nct_id,start_date,primary_completion__date,study_type,brief_title,overall_status,phase,sponsor,why_stopped,ctg_links,Abstract,Registry,Total_pubs,vaccine_trial_flag,Number_of_updates,US_site_flag,country,Has_Results,mapped_intervention,ArticleType
NCT04326790,2020-04-03,2020-08-31,Interventional,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,Recruiting,Phase 2,National and Kapodistrian University of Athens,NA,https://clinicaltrials.gov/ct2/show/NCT04326790,2,0,2,0,4,0,Gibraltar,0,colchicine|standard care,Clinical Trial Protocol|Journal Article/Journal Article|Randomized Controlled Trial
NCT04292964,2020-03-01,2020-03-13,Observational,Prognostic Factors of Patients With COVID-19,Completed,NA,Chongqing Medical University,NA,https://clinicaltrials.gov/ct2/show/NCT04292964,2,0,2,0,3,0,China,0,"NA",Journal Article|Observational Study/Journal Article|Multicenter Study|Observational Study
NCT04315948,2020-03-22,2023-03-31,Interventional,Trial of Treatments for COVID-19 in Hospitalized Adults,"Active, not recruiting",Phase 3,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",NA,https://clinicaltrials.gov/ct2/show/NCT04315948,3,0,3,0,7,0,Austria|Belgium|France|Luxembourg|Portugal,0,remdesivir|lopinavir/ritonavir|interferon|hydroxychloroquine|standard care|lopinavir|ritonavir,"Journal Article/Adaptive Clinical Trial|Clinical Trial Protocol|Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article"
NCT04323527,2020-03-23,2020-05-07,Interventional,Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2,Completed,Phase 2,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,NA,https://clinicaltrials.gov/ct2/show/NCT04323527,1,0,1,0,3,0,Brazil,0,chloroquine,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04279782,2020-01-20,2021-01-31,Observational,Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection,Recruiting,NA,"Third Affiliated Hospital, Sun Yat-Sen University",NA,https://clinicaltrials.gov/ct2/show/NCT04279782,1,0,1,0,1,0,China,0,comprehensive treatment,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04318366,2020-03-19,2022-03-19,Observational,"COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor",Recruiting,NA,UniversitÃ  Vita-Salute San Raffaele,NA,https://clinicaltrials.gov/ct2/show/NCT04318366,7,0,7,0,3,0,Italy,0,observational,Journal Article/Journal Article/Journal Article|Observational Study/Journal Article/Journal Article/Clinical Trial|Journal Article|Multicenter Study/Journal Article
NCT04355936,2020-05-19,2020-11-02,Interventional,Telmisartan for Treatment of COVID-19 Patients,Completed,Phase 4,Laboratorio Elea Phoenix S.A.,NA,https://clinicaltrials.gov/ct2/show/NCT04355936,1,0,1,0,8,0,Argentina,0,telmisartan|standard care,Journal Article
NCT04308668,2020-03-17,2020-05-20,Interventional,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Completed,Phase 3,University of Minnesota,NA,https://clinicaltrials.gov/ct2/show/NCT04308668,3,1,4,0,9,1,United States|Canada,0,hydroxychloroquine|placebo,"Clinical Trial Protocol|Journal Article|Multicenter Study|Randomized Controlled Trial/Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article|Multicenter Study|Randomized Controlled Trial/Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04321278,2020-03-28,2020-06-14,Interventional,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),Completed,Phase 3,Hospital Israelita Albert Einstein,NA,https://clinicaltrials.gov/ct2/show/NCT04321278,2,0,2,0,6,0,Brazil,0,hydroxychloroquine / azithromycin|hydroxychloroquine|azithromycin,"Editorial/Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04261517,2020-02-06,2020-02-25,Interventional,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Completed,Phase 3,Shanghai Public Health Clinical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04261517,1,0,1,0,3,0,China,0,hydroxychloroquine,Journal Article|Randomized Controlled Trial
NCT04276688,2020-02-10,2020-03-30,Interventional,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment",Completed,Phase 2,The University of Hong Kong,NA,https://clinicaltrials.gov/ct2/show/NCT04276688,2,0,2,0,2,0,Hong Kong,0,lopinavir/ritonavir|ribavirin|interferon|lopinavir|ritonavir,"Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Review"
NCT04367831,2020-05-02,2020-11-30,Interventional,Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19,Recruiting,Phase 4,Columbia University,NA,https://clinicaltrials.gov/ct2/show/NCT04367831,2,0,2,0,2,1,United States,0,enoxaparin|heparin|enoxaparin/lovenox|lovenox,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04345848,2020-04-28,2021-03-31,Interventional,Preventing COVID-19 Complications With Low- and High-dose Anticoagulation,Recruiting,Phase 3,"University Hospital, Geneva",NA,https://clinicaltrials.gov/ct2/show/NCT04345848,2,0,2,0,3,0,Switzerland,0,enoxaparin,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04372589,2020-05-20,2021-01-31,Interventional,Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC),"Active, not recruiting",Phase 2/Phase 3,University of Manitoba,NA,https://clinicaltrials.gov/ct2/show/NCT04372589,3,0,3,1,4,1,United States|Brazil|Canada|Mexico,0,heparin,"Journal Article/Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04366960,2020-05-14,2021-08-31,Interventional,Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients,Recruiting,Phase 3,Niguarda Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04366960,2,0,2,0,3,0,Italy,0,enoxaparin,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04257656,2020-02-06,2020-03-30,Interventional,A Trial of Remdesivir in Adults With Severe COVID-19,Terminated,Phase 3,Capital Medical University,"The epidemic of COVID-19 has been controlled well in China, no eligible patients can be
    enrolled at present.",https://clinicaltrials.gov/ct2/show/NCT04257656,2,0,2,0,3,0,China,0,remdesivir|placebo,Journal Article|Multicenter Study|Randomized Controlled Trial/Clinical Trial Protocol|Journal Article
NCT04329832,2020-03-30,2020-12-18,Interventional,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,"Active, not recruiting",Phase 2,"Intermountain Health Care, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04329832,2,0,2,0,3,1,United States,0,hydroxychloroquine|azithromycin,"Clinical Trial Protocol|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article"
NCT04374071,2020-03-12,2020-03-27,Observational,Early Short Course Corticosteroids in COVID-19,Completed,NA,Henry Ford Health System,NA,https://clinicaltrials.gov/ct2/show/NCT04374071,1,0,1,0,0,1,United States,0,methylprednisolone,Journal Article
NCT04280705,2020-02-21,2020-05-21,Interventional,Adaptive COVID-19 Treatment Trial (ACTT),Completed,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicaltrials.gov/ct2/show/NCT04280705,2,0,2,0,24,1,"United States|Denmark|Germany|Greece|Japan|Korea, Republic of|Mexico|Singapore|Spain|United Kingdom",1,placebo|remdesivir,"Clinical Trial, Phase III|Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article|Review"
NCT04313127,2020-03-16,2020-12-30,Interventional,Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults,"Active, not recruiting",Phase 1,CanSino Biologics Inc.,NA,https://clinicaltrials.gov/ct2/show/NCT04313127,1,0,1,1,4,0,China,0,adenovirus type 5 vector,"Clinical Trial, Phase I|Journal Article"
NCT04292899,2020-03-06,2020-04-09,Interventional,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe Coronavirus Disease (COVID-19),Completed,Phase 3,Gilead Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04292899,1,0,1,0,20,1,"United States|China|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Netherlands|Singapore|Spain|Sweden|Switzerland|Taiwan|United Kingdom",1,remdesivir|standard care,"Clinical Trial, Phase III|Comparative Study|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04321421,2020-03-17,2020-04-28,Interventional,Hyperimmune Plasma for Critical Patients With COVID-19,Completed,N/A,Foundation IRCCS San Matteo Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04321421,3,0,3,0,2,0,Italy,0,convalescent plasma,"Clinical Trial Protocol|Journal Article|Multicenter Study/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04324736,2020-03-10,2020-04-10,Observational,"""COVID-19 and Diabetes Outcomes""","Active, not recruiting",NA,Nantes University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04324736,2,0,2,0,6,0,France,0,no interventional study,"Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't/Letter|Comment"
NCT04354701,2020-03-17,2021-12-31,Observational [Patient Registry],COVID-19 and Cancer Consortium Registry,Recruiting,NA,Vanderbilt-Ingram Cancer Center,NA,https://clinicaltrials.gov/ct2/show/NCT04354701,1,0,1,0,4,1,United States,0,web-based redcap survey,"Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04332991,2020-04-02,2020-06-19,Interventional,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Completed,Phase 3,Massachusetts General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04332991,2,0,2,0,6,1,United States,0,hydroxychloroquine|placebo,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural/Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural"
NCT04330638,2020-04-03,2021-01-31,Interventional,Treatment of COVID-19 Patients With Anti-interleukin Drugs,"Active, not recruiting",Phase 3,"University Hospital, Ghent",NA,https://clinicaltrials.gov/ct2/show/NCT04330638,1,0,1,0,6,0,Belgium,0,standard care|anakinra|siltuximab|tocilizumab,Clinical Trial Protocol|Letter
NCT04343768,2020-04-09,2020-04-27,Interventional,"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial",Completed,Phase 2,Shahid Beheshti University of Medical Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04343768,1,0,1,0,3,0,"Iran, Islamic Republic of",0,hydroxychloroquine|lopinavir/ritonavir|interferon|lopinavir|ritonavir,Clinical Trial Protocol|Letter
NCT04328961,2020-03-31,2020-09-24,Interventional,Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP),Completed,Phase 2/Phase 3,University of Washington,NA,https://clinicaltrials.gov/ct2/show/NCT04328961,2,0,2,0,5,1,United States,0,hydroxychloroquine|vitamin c,Clinical Trial Protocol|Letter/Journal Article
NCT04331171,2020-03-17,2020-11-15,Observational [Patient Registry],Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' Triage,Recruiting,NA,Weprom,NA,https://clinicaltrials.gov/ct2/show/NCT04331171,2,0,2,0,3,0,France,0,web application users,Journal Article/Journal Article|Observational Study
NCT04328441,2020-03-25,2021-03-31,Interventional,Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine,"Active, not recruiting",Phase 3,UMC Utrecht,NA,https://clinicaltrials.gov/ct2/show/NCT04328441,1,0,1,1,3,0,Netherlands,0,bcg|placebo,Clinical Trial Protocol|Letter
NCT04360980,2020-03-20,2021-09-01,Interventional,The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection,Recruiting,Phase 2,Shahid Beheshti University of Medical Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04360980,1,0,1,0,3,0,"Iran, Islamic Republic of",0,colchicine,Clinical Trial Protocol|Letter
NCT04333589,2020-04-01,2020-06-01,Interventional,Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive,Recruiting,N/A,Peking University First Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04333589,1,0,1,0,2,0,China,0,favipiravir,Clinical Trial Protocol|Letter
NCT04316377,2020-03-25,2020-05-25,Interventional,Norwegian Coronavirus Disease 2019 Study,"Active, not recruiting",Phase 4,"University Hospital, Akershus",NA,https://clinicaltrials.gov/ct2/show/NCT04316377,2,0,2,0,3,0,Norway,0,hydroxychloroquine,"Clinical Trial Protocol|Letter/Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04326920,2020-03-24,2021-01-31,Interventional,Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC),"Active, not recruiting",Phase 4,"University Hospital, Ghent",NA,https://clinicaltrials.gov/ct2/show/NCT04326920,2,0,2,0,4,0,Belgium,0,sargramostim|control,"Clinical Trial Protocol|Letter/Journal Article|Research Support, Non-U.S. Gov't|Review"
NCT04306393,2020-03-21,2021-03-21,Interventional,Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19,Recruiting,Phase 2,Massachusetts General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04306393,1,0,1,0,7,1,United States,0,nitric oxide,Preprint
NCT04335786,2020-04-17,2020-12-31,Interventional,Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease,Recruiting,Phase 4,Radboud University,NA,https://clinicaltrials.gov/ct2/show/NCT04335786,1,0,1,0,6,0,Netherlands,0,diovan|placebo,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04341493,2020-04-06,2020-08-30,Interventional,Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19,Recruiting,Phase 4,Materno-Perinatal Hospital of the State of Mexico,NA,https://clinicaltrials.gov/ct2/show/NCT04341493,1,0,1,0,2,0,Mexico,0,nitazoxanide|hydroxychloroquine,Clinical Trial Protocol|Letter
NCT04334265,2020-04-01,2020-06-01,Interventional,Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019,Recruiting,N/A,Peking University First Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04334265,1,0,1,0,1,0,China,0,anluohuaxian,Clinical Trial Protocol|Letter
NCT04359810,2020-04-21,2020-12-31,Interventional,Plasma Therapy of COVID-19 in Severely Ill Patients,Recruiting,Phase 2,Columbia University,NA,https://clinicaltrials.gov/ct2/show/NCT04359810,1,0,1,0,3,1,United States|Brazil,0,convalescent plasma|plasma,Clinical Trial Protocol|Letter
NCT04338958,2020-04-22,2021-07-31,Interventional,Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation,Recruiting,Phase 2,University of Jena,NA,https://clinicaltrials.gov/ct2/show/NCT04338958,1,0,1,0,4,0,Germany,0,ruxolitinib,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04368338,2020-04-28,2021-01-28,Observational,Lung Ultrasound to Diagnose COVID-19,Recruiting,NA,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicaltrials.gov/ct2/show/NCT04368338,1,0,1,0,1,0,France,0,pcr|lung ultrasound,Journal Article|Observational Study
NCT04322396,2020-04-06,2020-10-31,Interventional,Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,Recruiting,Phase 2,"Chronic Obstructive Pulmonary Disease Trial Network, Denmark",NA,https://clinicaltrials.gov/ct2/show/NCT04322396,2,0,2,0,3,0,Denmark,0,placebo|azithromycin|hydroxychloroquine,Clinical Trial Protocol|Letter/Journal Article|Multicenter Study|Randomized Controlled Trial
NCT04352517,2020-03-16,2020-08-31,Observational,Influence Physical Activity Psychological Responses COVID-19 Pandemic,Recruiting,NA,University of Extremadura,NA,https://clinicaltrials.gov/ct2/show/NCT04352517,1,0,1,0,1,0,Brazil|Chile|Uruguay,0,online survey,Journal Article|Multicenter Study|Observational Study
NCT04336254,2020-04-06,2020-12-31,Interventional,Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients,Recruiting,Phase 1/Phase 2,Renmin Hospital of Wuhan University,NA,https://clinicaltrials.gov/ct2/show/NCT04336254,1,0,1,0,0,0,China,0,mesenchymal stem cells|placebo|utooth btc),"Clinical Trial Protocol|Clinical Trial, Phase I|Clinical Trial, Phase II|Letter"
NCT04369469,2020-05-11,2021-05-31,Interventional,Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia,"Active, not recruiting",Phase 3,Alexion Pharmaceuticals,NA,https://clinicaltrials.gov/ct2/show/NCT04369469,2,0,2,0,8,1,United States|France|Japan|Spain|United Kingdom,0,ravulizumab|best supportive care,"Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't|Review/Clinical Trial Protocol|Letter"
NCT04354259,2020-05-13,2020-08-01,Interventional,Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19,Recruiting,Phase 2,"University Health Network, Toronto",NA,https://clinicaltrials.gov/ct2/show/NCT04354259,2,0,2,0,1,0,Canada,0,peginterferon|placebo,"Journal Article|Review/Journal Article|Research Support, Non-U.S. Gov't"
NCT04355364,2020-04-21,2020-11-21,Interventional,Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE),Recruiting,Phase 3,Fondation Ophtalmologique Adolphe de Rothschild,NA,https://clinicaltrials.gov/ct2/show/NCT04355364,1,0,1,0,7,0,France,0,pulmozyme|standard care,Clinical Trial Protocol|Letter|Multicenter Study
NCT04331574,2020-03-10,2020-04-10,Observational [Patient Registry],Renin-Angiotensin System Inhibitors and COVID-19,Recruiting,NA,Societa Italiana dell'Ipertensione Arteriosa,NA,https://clinicaltrials.gov/ct2/show/NCT04331574,2,0,2,0,0,0,Italy,0,"NA","Journal Article|Multicenter Study|Observational Study|Research Support, Non-U.S. Gov't/Clinical Trial|Journal Article|Multicenter Study|Observational Study|Research Support, Non-U.S. Gov't"
NCT04365959,2020-03-20,2020-04-09,Observational,The Prone Position in Covid-19 Affected Patients,"Active, not recruiting",NA,University of Milano Bicocca,NA,https://clinicaltrials.gov/ct2/show/NCT04365959,1,0,1,0,1,0,Italy,0,prone positioning,"Clinical Trial|Journal Article|Research Support, Non-U.S. Gov't"
NCT04368156,2020-04-20,2020-07-31,Interventional,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,Recruiting,N/A,Hospital ClÃ­nico Universitario de Valencia,NA,https://clinicaltrials.gov/ct2/show/NCT04368156,1,0,1,0,0,0,Spain,0,gammacoreâ® (vagus nerve stimulation),Clinical Trial Protocol|Letter
NCT04348513,2020-05-29,2021-05-02,Interventional,Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection,Recruiting,Phase 2,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,NA,https://clinicaltrials.gov/ct2/show/NCT04348513,1,0,1,0,1,0,Greece,0,t3 solution|placebo,"Clinical Trial Protocol|Clinical Trial, Phase II|Letter|Multicenter Study"
NCT04338672,2020-04-05,2021-04-01,Observational,The Impact of the Covid-19 Outbreak on Emergency Room Attendances of Surgical Patients,Recruiting,NA,Sheba Medical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04338672,1,0,1,0,1,0,Israel,0,covid-19 pandemic,Journal Article|Observational Study
NCT04334291,2020-03-23,2020-05-01,Observational [Patient Registry],"International COVID19 Clinical Evaluation Registry,",Completed,NA,"St Carlos Hospital, Madrid, Spain",NA,https://clinicaltrials.gov/ct2/show/NCT04334291,5,7,12,0,2,0,Spain,0,observational,"Journal Article|Research Support, Non-U.S. Gov't/Journal Article/Journal Article/Journal Article/Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Multicenter Study/Journal Article/Journal Article/Journal Article/Journal Article/Journal Article"
NCT04327531,2020-03-26,2020-05-22,Observational,"Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study",Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04327531,1,0,1,0,4,0,Turkey,0,turkish physicians,Journal Article
NCT04339608,2020-04-02,2020-05-30,Observational,Max COVID19- Study,Recruiting,NA,Max Healthcare Insititute Limited,NA,https://clinicaltrials.gov/ct2/show/NCT04339608,1,0,1,0,0,0,India,0,"NA",Journal Article
NCT04380818,2020-06-05,2021-05-04,Interventional,Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19,Recruiting,N/A,Grupo de InvestigaciÃ³n ClÃ­nica en OncologÃ­a Radioterapia,NA,https://clinicaltrials.gov/ct2/show/NCT04380818,1,0,1,0,2,0,Spain,0,radiotherapy|hydroxychloroquine|lopinavir/ritonavir|tocilizumab|azithromycin|corticosteroid|heparin|oxygen|ritonavir|lopinavir,Journal Article
NCT04410562,2020-05-13,2021-05-13,Interventional,Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum,Recruiting,Phase 3,Barcelona Institute for Global Health,NA,https://clinicaltrials.gov/ct2/show/NCT04410562,1,0,1,0,1,0,Spain,0,hydroxychloroquine|placebo,Clinical Trial Protocol|Letter
NCT04307693,2020-03-11,2020-04-30,Interventional,Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19),Terminated,Phase 2,Asan Medical Center,Terminated early because no patients were further enrolled since mid-Apr 2020.,https://clinicaltrials.gov/ct2/show/NCT04307693,1,0,1,0,2,0,"Korea, Republic of",0,lopinavir/ritonavir|hydroxychloroquine|lopinavir|ritonavir,Journal Article|Comment
NCT04368676,2020-06-25,2021-06-30,Interventional,Breath Regulation and Yogic Exercise An Online Therapy for Calm and Happiness,Recruiting,Early Phase 1,Lawson Health Research Institute,NA,https://clinicaltrials.gov/ct2/show/NCT04368676,2,0,2,0,1,0,Canada,0,sudarshan kriya yoga (sky)|health enhancement program,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review/Clinical Trial Protocol|Clinical Trial, Phase I|Clinical Trial, Phase II|Letter"
NCT04390464,2020-05-08,2021-05-07,Interventional,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R),Recruiting,Phase 4,Cambridge University Hospitals NHS Foundation Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04390464,1,0,1,0,1,0,United Kingdom,0,ravulizumab|baricitinib|standard care,"Clinical Trial Protocol|Clinical Trial, Phase IV|Letter"
NCT04339816,2020-05-13,2020-11-04,Interventional,Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial,Terminated,Phase 3,"Charles University, Czech Republic",Steering Committee decision in accordance with stopping rule 1: Emergence of new data,https://clinicaltrials.gov/ct2/show/NCT04339816,1,0,1,0,3,0,Czechia,0,azithromycin|hydroxychloroquine|placebo,Clinical Trial Protocol|Journal Article|Multicenter Study
NCT04264533,2020-02-14,2020-03-02,Interventional,Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia,Terminated,Phase 2,Zhongnan Hospital,"the study was started in the second half of the outbreak, and the number of qualifying COVID-19
    patients decreased with the control of the epidemic so that we had to stop our trial before
    reaching the predefined sample size.",https://clinicaltrials.gov/ct2/show/NCT04264533,1,0,1,0,2,0,China,0,vitamin c|water,"Clinical Trial Protocol|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04321265,2020-03-19,2021-09-30,Observational,Outcomes and Prognostic Factors in COVID-19,Recruiting,NA,"Heinrich-Heine University, Duesseldorf",NA,https://clinicaltrials.gov/ct2/show/NCT04321265,1,0,1,0,4,0,Denmark|France|Germany|Norway,0,"NA",Journal Article|Multicenter Study
NCT04471701,2020-04-13,2020-07-31,Observational,Italian Web-based Cross-sectional Survey on COVID-19,Recruiting,NA,"Institute of Biomedical Technologies-National Research Council, Italy",NA,https://clinicaltrials.gov/ct2/show/NCT04471701,1,0,1,0,1,0,Italy,0,environmental exposure/clinical features|environmental exposure|clinical features,Journal Article
NCT04312009,2020-04-13,2021-04-01,Interventional,Losartan for Patients With COVID-19 Requiring Hospitalization,Recruiting,Phase 2,University of Minnesota,NA,https://clinicaltrials.gov/ct2/show/NCT04312009,1,0,1,0,12,1,United States,0,losartan|placebo,Journal Article
NCT04335123,2020-04-04,2020-06-21,Interventional,Study of Open Label Losartan in COVID-19,Completed,Phase 1,University of Kansas Medical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04335123,1,0,1,0,3,1,United States,0,losartan,Journal Article
NCT04311177,2020-04-09,2021-04-01,Interventional,Losartan for Patients With COVID-19 Not Requiring Hospitalization,"Active, not recruiting",Phase 2,University of Minnesota,NA,https://clinicaltrials.gov/ct2/show/NCT04311177,1,0,1,0,9,1,United States,0,losartan|placebo,Journal Article
NCT04283461,2020-03-16,2021-11-22,Interventional,Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19),"Active, not recruiting",Phase 1,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicaltrials.gov/ct2/show/NCT04283461,2,0,2,1,12,1,United States,0,mrna-1273,"Clinical Trial, Phase I|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Clinical Trial, Phase I|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04252274,2020-01-30,2020-08-31,Interventional,Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19,Recruiting,Phase 3,Shanghai Public Health Clinical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04252274,1,0,1,0,2,0,China,0,darunavir/cobicistat|darunavir|cobicistat,Journal Article
NCT04251871,2020-01-22,2021-01-22,Interventional,Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection,Recruiting,N/A,Beijing 302 Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04251871,1,0,1,0,1,0,China,0,"conventional medicines (oxygen therapy, alfa interferon via aerosol inhalation,/lopinavir/ritonavir)/traditional chinese medicines (tcms) granules|conventional medicines (oxygen therapy, alfa interferon via aerosol inhalation,/lopinavir/ritonavir)|conventional medicines (oxygen therapy, alfa interferon via aerosol inhalation,|lopinavir|ritonavir|traditional chinese medicine",Journal Article|Randomized Controlled Trial
NCT04370067,2020-05-01,2021-05-01,Observational [Patient Registry],HUNgarian COronaVirus Disease-19 Epidemiological Research,Recruiting,NA,Semmelweis University Heart and Vascular Center,NA,https://clinicaltrials.gov/ct2/show/NCT04370067,1,0,1,0,2,0,Hungary,0,"NA","Journal Article|Research Support, Non-U.S. Gov't"
NCT04381936,2020-03-19,2021-12-31,Interventional,Randomised Evaluation of COVID-19 Therapy,Recruiting,Phase 2/Phase 3,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04381936,2,2,4,0,6,0,United Kingdom,0,lopinavir/ritonavir|corticosteroid|hydroxychloroquine|azithromycin|convalescent plasma|tocilizumab|immunoglobulin|synthetic neutralising antibodies|aspirin|colchicine,Journal Article/Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial/Journal Article/Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial
NCT04368390,2020-04-03,2021-04-30,Observational,Neuroradiolological Analysis of COVID-19 Patients,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicaltrials.gov/ct2/show/NCT04368390,1,0,1,0,2,0,France,0,"NA",Journal Article|Multicenter Study
NCT04361474,2020-05-18,2020-11-24,Interventional,Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity,"Active, not recruiting",Phase 3,Fondation Ophtalmologique Adolphe de Rothschild,NA,https://clinicaltrials.gov/ct2/show/NCT04361474,1,0,1,0,4,0,France,0,budesonide|serum,Clinical Trial Protocol|Letter|Multicenter Study
NCT04279899,2020-02-01,2020-11-30,Observational,The Investigation of the Neonates With or With Risk of COVID-19,Recruiting,NA,Children's Hospital of Fudan University,NA,https://clinicaltrials.gov/ct2/show/NCT04279899,1,0,1,0,0,0,China,0,"NA",Journal Article|Multicenter Study|Observational Study
NCT04403607,2020-05-22,2020-09-30,Observational,Cardiac Imaging in SARS-CoV-2 (COVID-19),Recruiting,NA,NHS Greater Glasgow and Clyde,NA,https://clinicaltrials.gov/ct2/show/NCT04403607,1,0,1,0,2,0,United Kingdom,0,"NA",Journal Article|Multicenter Study|Observational Study
NCT04324606,2020-04-23,2021-10-31,Interventional,A Study of a Candidate COVID-19 Vaccine (COV001),"Active, not recruiting",Phase 1/Phase 2,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04324606,2,0,2,1,12,0,United Kingdom,0,chadox1|menacwy|paracetamol,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04341389,2020-04-12,2021-01-31,Interventional,A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector),"Active, not recruiting",Phase 2,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",NA,https://clinicaltrials.gov/ct2/show/NCT04341389,1,0,1,1,3,0,China,0,adenovirus type 5 vector|placebo,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04322123,2020-04-01,2020-08-30,Interventional,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),"Active, not recruiting",Phase 3,Hospital do Coracao,NA,https://clinicaltrials.gov/ct2/show/NCT04322123,1,0,1,0,6,0,Brazil,0,hydroxychloroquine|hydroxychloroquine / azithromycin|azithromycin,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04441489,2020-03-27,2020-05-03,Observational,Assessment of Lung Inflammation With FDG PET/CT in COVID-19,Completed,NA,Centre Hospitalier Princesse Grace,NA,https://clinicaltrials.gov/ct2/show/NCT04441489,1,0,1,0,0,0,Monaco,0,"NA",Clinical Trial|Journal Article
NCT04323644,2020-01-01,2020-09-30,Observational,Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg),Recruiting,NA,University of Birmingham,NA,https://clinicaltrials.gov/ct2/show/NCT04323644,1,0,1,0,1,0,Spain,0,surgery,Journal Article
NCT04368975,2020-03-12,2020-04-21,Observational [Patient Registry],ARDS Caused by COVID-19,Recruiting,NA,Hospital Clinic of Barcelona,NA,https://clinicaltrials.gov/ct2/show/NCT04368975,1,0,1,0,0,0,Spain,0,"NA","Journal Article|Multicenter Study|Observational Study|Research Support, Non-U.S. Gov't"
NCT04393246,2020-07-03,2021-02-15,Interventional,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms,Recruiting,Phase 2/Phase 3,Cambridge University Hospitals NHS Foundation Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04393246,1,0,1,0,2,0,United Kingdom,0,edp1815|dapagliflozin|ambrisentan|standard care,"Clinical Trial Protocol|Clinical Trial, Phase II|Clinical Trial, Phase III|Letter"
NCT04363827,2020-05-14,2020-09-30,Interventional,Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19),Recruiting,Phase 2,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,NA,https://clinicaltrials.gov/ct2/show/NCT04363827,1,0,1,0,2,0,Italy,0,hydroxychloroquine,Clinical Trial Protocol|Comparative Study|Journal Article|Observational Study
NCT04433910,2020-08-30,2021-01-21,Interventional,A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19,"Active, not recruiting",Phase 2,Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen,NA,https://clinicaltrials.gov/ct2/show/NCT04433910,1,0,1,0,3,0,Germany,0,convalescent plasma,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04377711,2020-06-08,2020-09-01,Interventional,A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients,Recruiting,Phase 3,Covis Pharma S.Ã .r.l.,NA,https://clinicaltrials.gov/ct2/show/NCT04377711,1,0,1,0,2,1,United States,0,ciclesonide|placebo,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04355637,2020-04-21,2021-08-31,Interventional,Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia,Recruiting,Phase 4,Fundacion Clinic per a la Recerca BiomÃ©dica,NA,https://clinicaltrials.gov/ct2/show/NCT04355637,1,0,1,0,4,0,Argentina|Spain,0,budesonide,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04330586,2020-04-01,2021-03-31,Interventional,A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19,Recruiting,Phase 2,Korea University Guro Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04330586,1,0,1,0,2,0,"Korea, Republic of",0,ciclesonide,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04331470,2020-04-04,2020-04-20,Interventional,Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19,Recruiting,Phase 2/Phase 3,Fasa University of Medical Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04331470,1,0,1,0,2,0,"Iran, Islamic Republic of",0,levamisole / budesonide/formoterol|lopinavir/ritonavir / hydoxychloroquine|levamisole|budesonide|formoterol|lopinavir|ritonavir|hydroxychloroquine,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04416399,2020-07-16,2020-11-15,Interventional,STerOids in COVID-19 Study,Recruiting,Phase 2,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04416399,1,0,1,0,4,0,United Kingdom,0,budesonide,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04331509,2020-03-23,2022-03-23,Observational,COVID-19 Symptom Tracker,Recruiting,NA,King's College London,NA,https://clinicaltrials.gov/ct2/show/NCT04331509,1,0,1,0,2,1,United States|United Kingdom,0,no intervention,"Journal Article|Observational Study|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04346186,2020-04-15,2020-10-01,Observational,COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff,Enrolling by invitation,NA,Herlev Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04346186,1,0,1,0,1,0,Denmark,0,igm/igg rapid test|igm|igg antibody test|igg,"Journal Article|Observational Study|Research Support, Non-U.S. Gov't"
NCT04296643,2020-04-01,2021-02-01,Interventional,Medical Masks vs N95 Respirators for COVID-19,Recruiting,N/A,McMaster University,NA,https://clinicaltrials.gov/ct2/show/NCT04296643,1,0,1,0,1,0,Canada|Israel,0,medical mask|n95 respirator,Journal Article
NCT04392245,2020-04-15,2020-04-26,Observational,Proctologic Practice and Covid-19,Completed,NA,Societa Italiana di Chirurgia ColoRettale,NA,https://clinicaltrials.gov/ct2/show/NCT04392245,1,0,1,0,0,0,Italy,0,"NA",Journal Article
NCT04338698,2020-04-22,2020-09-01,Interventional,"Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT",Recruiting,Phase 3,University of Health Sciences Lahore,NA,https://clinicaltrials.gov/ct2/show/NCT04338698,1,0,1,0,2,0,Pakistan,0,hydroxychloroquine|oseltamivir|azithromycin,Clinical Trial Protocol|Letter|Multicenter Study|Observational Study|Randomized Controlled Trial
NCT04401202,2020-05-21,2020-12-31,Interventional,Nigella Sativa in COVID-19,Recruiting,Phase 2,King Abdulaziz University,NA,https://clinicaltrials.gov/ct2/show/NCT04401202,1,0,1,0,0,0,Saudi Arabia,0,nigella sativa,"Clinical Trial Protocol|Clinical Trial, Phase II|Letter"
NCT04401540,2020-05-01,2020-10-30,Observational [Patient Registry],Characteristics of Neonatal Covid-19 in Turkey,Recruiting,NA,Recep Tayyip Erdogan University Training and Research Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04401540,1,3,4,0,2,0,Turkey,0,"NA",Journal Article/Journal Article|Review/Journal Article
NCT04434131,2020-04-28,2021-04-28,Interventional,Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19,Recruiting,Phase 2,University of New Mexico,NA,https://clinicaltrials.gov/ct2/show/NCT04434131,2,0,2,0,0,1,United States,0,convalescent plasma,"Clinical Trial|Journal Article/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04316949,2020-03-20,2020-04-30,Observational,Predictors of Respiratory Failure in SARS-Cov-2 Infection,Recruiting,NA,University of Bologna,NA,https://clinicaltrials.gov/ct2/show/NCT04316949,1,0,1,0,4,0,Italy,0,"NA",Journal Article|Multicenter Study
NCT04368728,2020-04-29,2021-08-03,Interventional,"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals","Active, not recruiting",Phase 2/Phase 3,BioNTech SE,NA,https://clinicaltrials.gov/ct2/show/NCT04368728,4,0,4,1,23,1,United States|Argentina|Brazil|Germany|South Africa|Turkey,0,bnt162b1|bnt162b2|placebo,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial/Clinical Trial, Phase I|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Clinical Trial, Phase II|Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article"
NCT04343729,2020-04-18,2020-06-16,Interventional,Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19,"Active, not recruiting",Phase 2,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,NA,https://clinicaltrials.gov/ct2/show/NCT04343729,1,0,1,0,6,0,Brazil,0,methylprednisolone|placebo,Journal Article
NCT04394000,2020-05-04,2020-05-15,Observational [Patient Registry],Impact of an Intensified Thromboprofylaxis Protocol in COVID-19,Completed,NA,Jessa Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04394000,1,0,1,0,0,0,Belgium,0,thromboprofylaxis protocol|standard care,Journal Article
NCT04343976,2020-06-22,2021-04-01,Interventional,Pegylated Interferon Lambda Treatment for COVID-19,Enrolling by invitation,Phase 2,Massachusetts General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04343976,1,0,1,0,3,1,United States,0,peginterferon,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04385095,2020-03-16,2021-02-01,Interventional,Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection,Recruiting,Phase 2,Synairgen Research Ltd.,NA,https://clinicaltrials.gov/ct2/show/NCT04385095,2,0,2,0,1,0,United Kingdom,0,sng001|placebo,"Journal Article|Research Support, Non-U.S. Gov't/Journal Article"
NCT04344600,2020-05-29,2021-06-30,Interventional,Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection,Recruiting,Phase 2,Johns Hopkins University,NA,https://clinicaltrials.gov/ct2/show/NCT04344600,1,0,1,0,3,1,United States,0,peginterferon|saline,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04347993,2020-03-27,2021-04-30,Observational [Patient Registry],"A Prospective ""Universal"" Observational Database for COVID-19",Recruiting,NA,Hackensack Meridian Health,NA,https://clinicaltrials.gov/ct2/show/NCT04347993,2,0,2,0,1,1,United States,0,"NA",Journal Article|Multicenter Study|Observational Study/Journal Article
NCT04345614,2020-04-08,2021-03-31,Interventional,A Study of Auxora in Patients With Severe COVID-19 Pneumonia,Recruiting,Phase 2,"CalciMedica, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04345614,1,0,1,0,15,1,United States|Puerto Rico,0,auxora|placebo,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04352556,2020-04-07,2021-04-30,Observational,COVID19-hematological Malignancies: the Italian Hematology Alliance,Recruiting,NA,Ospedale di Circolo - Fondazione Macchi,NA,https://clinicaltrials.gov/ct2/show/NCT04352556,1,0,1,0,1,0,Italy,0,"NA",Journal Article|Multicenter Study|Observational Study
NCT04325061,2020-04-03,2020-06-19,Interventional,Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19,Terminated,Phase 4,Dr. Negrin University Hospital,Lack of enrollment,https://clinicaltrials.gov/ct2/show/NCT04325061,1,2,3,0,8,0,Spain,0,dexamethasone,"Clinical Trial Protocol|Journal Article|Multicenter Study/Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04375410,2020-04-22,2020-04-30,Observational,Consequences of Intensified Handwash and Hand Disinfection Among Children During the COVID19 Pandemic,Enrolling by invitation,NA,Vendsyssel Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04375410,1,0,1,0,0,0,Denmark,0,"NA",Journal Article|Multicenter Study|Observational Study
NCT04381962,2020-05-29,2020-09-13,Interventional,A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2),Recruiting,Phase 3,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04381962,1,0,1,0,1,0,United Kingdom,0,azithromycin,"Clinical Trial Protocol|Clinical Trial, Phase II|Clinical Trial, Phase III|Comparative Study|Journal Article|Multicenter Study"
NCT04438629,2020-03-26,2020-06-10,Observational,Evaluation of Immune Response in COVID-19 Patients,Recruiting,NA,Azienda Ospedaliera Universitaria Integrata Verona,NA,https://clinicaltrials.gov/ct2/show/NCT04438629,1,0,1,0,1,0,Italy,0,covid-19 treatment,Clinical Trial|Journal Article|Multicenter Study|Observational Study
NCT04412057,2020-06-09,2020-10-31,Interventional,Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury,Recruiting,Phase 2,Cerecor Inc,NA,https://clinicaltrials.gov/ct2/show/NCT04412057,1,0,1,0,5,1,United States,0,cerc-002|placebo,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04292730,2020-03-15,2020-04-29,Interventional,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Completed,Phase 3,Gilead Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04292730,1,1,2,0,20,1,"Japan|United States|China|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Singapore|Spain|Sweden|Switzerland|Taiwan|United Kingdom",1,remdesivir|standard care,"Clinical Trial, Phase III|Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Clinical Trial, Phase III|Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04370288,2020-04-19,2020-09-20,Interventional,Clinical Application of Methylene Blue for Treatment of Covid-19 Patients,Recruiting,Phase 1,Mashhad University of Medical Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04370288,1,0,1,0,1,0,"Iran, Islamic Republic of",0,methylene blue/ vitamin c/n-acetyl cysteine,Case Reports|Journal Article
NCT04262921,2020-02-08,2020-08-07,Observational,French COVID Cohort,Recruiting,NA,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",NA,https://clinicaltrials.gov/ct2/show/NCT04262921,2,0,2,0,2,0,France,0,"NA","Case Reports|Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't"
NCT04337541,2020-04-02,2020-06-02,Interventional,Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,Completed,N/A,"Rigshospitalet, Denmark",NA,https://clinicaltrials.gov/ct2/show/NCT04337541,2,0,2,0,1,0,Denmark,0,surgical facial mask,Journal Article|Randomized Controlled Trial/Journal Article
NCT04357730,2020-05-14,2021-09-30,Interventional,Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection,Recruiting,Phase 2,Denver Health and Hospital Authority,NA,https://clinicaltrials.gov/ct2/show/NCT04357730,1,0,1,0,8,1,United States,0,activase,Journal Article
NCT04252885,2020-01-28,2020-04-30,Interventional,The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection,Completed,Phase 4,Guangzhou 8th People's Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04252885,1,0,1,0,1,0,China,0,lopinavir/ritonavir|arbidol|lopinavir|ritonavir,Journal Article
NCT04395105,2020-05-21,2020-12-31,Interventional,"Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial",Recruiting,Phase 3,Centro de EducaciÃ³n Medica e Investigaciones ClÃ­nicas Norberto Quirno,NA,https://clinicaltrials.gov/ct2/show/NCT04395105,1,0,1,0,3,0,Argentina,0,dexamethasone,Clinical Trial Protocol|Letter|Multicenter Study|Randomized Controlled Trial
NCT04420741,2020-06-15,2021-05-31,Interventional,Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure,Recruiting,Phase 2,"Rigshospitalet, Denmark",NA,https://clinicaltrials.gov/ct2/show/NCT04420741,1,0,1,0,5,0,Denmark,0,iloprost|saline,Clinical Trial Protocol|Letter|Multicenter Study|Randomized Controlled Trial
NCT04378595,2020-04-10,2020-12-30,Observational,Assessing Pediatric Food Insecurity During the COVID-19 Pandemic in Austin,Recruiting,NA,University of Texas at Austin,NA,https://clinicaltrials.gov/ct2/show/NCT04378595,1,0,1,0,1,1,United States,0,during covid-19 pandemic|after covid-19 pandemic,Journal Article
NCT04378582,2020-05-07,2020-07-28,Observational,Characteristics and Outcomes of Patients With COVID-19 Admitted to the ICU,Completed,NA,University of Sao Paulo General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04378582,1,0,1,0,3,0,Brazil,0,risk factors,Journal Article
NCT04327401,2020-04-13,2020-07-22,Interventional,COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III,Terminated,Phase 3,Hospital Sirio-Libanes,"The Data Monitoring Committee recommended to stop the trial based on the Recovery Trial
    results, which was accepted by the CoDEX Steering Committee.",https://clinicaltrials.gov/ct2/show/NCT04327401,1,0,1,0,5,0,Brazil,0,dexamethasone,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04305574,2020-03-07,2020-04-21,Observational,Social Media Use During COVID-19,Completed,NA,Yale-NUS College,NA,https://clinicaltrials.gov/ct2/show/NCT04305574,1,0,1,0,2,0,Singapore,0,use of social media during covid-19,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04368988,2020-05-25,2020-12-01,Interventional,Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant,"Active, not recruiting",Phase 1/Phase 2,Novavax,NA,https://clinicaltrials.gov/ct2/show/NCT04368988,3,0,3,1,5,1,United States|Australia,0,sars-cov-2 rs|sars-cov-2 rs/matrix-m1 adjuvant|placebo|adjuvant|21 - phase 2,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't"
NCT04338841,2020-04-09,2020-06-17,Interventional,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection,Completed,N/A,"University Hospital, Angers",NA,https://clinicaltrials.gov/ct2/show/NCT04338841,1,0,1,0,2,0,Belgium|France|Monaco,0,home-cov rule implementation,Journal Article
NCT04445935,2020-06-28,2020-09-28,Interventional,Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial,Recruiting,Phase 4,Hamad Medical Corporation,NA,https://clinicaltrials.gov/ct2/show/NCT04445935,1,0,1,0,0,0,Qatar,0,bivalirudin|standard care,Clinical Trial Protocol|Equivalence Trial|Letter
NCT04436471,2020-06-17,2020-08-03,Interventional,"An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" Vaccine Against COVID-19",Completed,Phase 1/Phase 2,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,https://clinicaltrials.gov/ct2/show/NCT04436471,1,0,1,1,3,0,Russian Federation,0,gam-covid-vac,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't"
NCT04437875,2020-06-17,2020-08-03,Interventional,"An Open Study of the Safety, Tolerability and Immunogenicity of ""Gam-COVID-Vac Lyo"" Vaccine Against COVID-19",Completed,Phase 1/Phase 2,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,https://clinicaltrials.gov/ct2/show/NCT04437875,1,0,1,1,3,0,Russian Federation,0,gam-covid-vac lyo,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't"
NCT04333849,2020-03-25,2020-05-11,Observational,Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19,Completed,NA,"University Hospital, Angers",NA,https://clinicaltrials.gov/ct2/show/NCT04333849,1,0,1,0,2,0,France,0,"NA",Clinical Trial|Journal Article
NCT04347681,2020-04-18,2020-12-31,Interventional,Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19,Recruiting,Phase 2,King Fahad Specialist Hospital Dammam,NA,https://clinicaltrials.gov/ct2/show/NCT04347681,2,0,2,0,3,0,Saudi Arabia,0,convalescent plasma,Journal Article/Journal Article
NCT04400799,2020-06-15,2021-03-14,Interventional,Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19,Recruiting,Phase 3,University of Zurich,NA,https://clinicaltrials.gov/ct2/show/NCT04400799,1,0,1,0,1,0,Switzerland,0,enoxaparin|0.4ml inj syringe 0.4ml,Clinical Trial Protocol|Letter
NCT04357808,2020-04-13,2020-12-31,Interventional,Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID),"Active, not recruiting",Phase 2,FundaciÃ³n de InvestigaciÃ³n BiomÃ©dica - Hospital Universitario de La Princesa,NA,https://clinicaltrials.gov/ct2/show/NCT04357808,1,0,1,0,2,0,Spain,0,sarilumab|standard care,Clinical Trial Protocol|Letter
NCT04396197,2020-03-01,2020-05-08,Observational,Physical Activity Levels in COVID-19 Patients Admitted to Intensive Care,Completed,NA,University Hospital Birmingham NHS Foundation Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04396197,1,0,1,0,0,0,United Kingdom,0,physiotherapy,Journal Article|Observational Study
NCT04399317,2020-05-28,2020-07-31,Interventional,Flow Controlled Ventilation in ARDS Associated With COVID-19,Recruiting,N/A,Hamad Medical Corporation,NA,https://clinicaltrials.gov/ct2/show/NCT04399317,1,0,1,0,1,0,Qatar,0,flow controlled ventilation (evone-ventilator),Clinical Trial Protocol|Letter
NCT04327206,2020-03-30,2021-06-30,Interventional,BCG Vaccination to Protect Healthcare Workers Against COVID-19,Recruiting,Phase 3,Murdoch Childrens Research Institute,NA,https://clinicaltrials.gov/ct2/show/NCT04327206,1,0,1,1,10,0,Australia|Brazil|Netherlands|Spain|United Kingdom,0,bcg|saline,"Journal Article|Research Support, Non-U.S. Gov't|Review"
NCT04352959,2020-04-27,2020-12-11,Interventional,COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses,Completed,N/A,Claude Bernard University,NA,https://clinicaltrials.gov/ct2/show/NCT04352959,2,0,2,0,3,0,France,0,mouthrinse with bãªta-cyclodextrin/citrox|mouthrinse without bãªta-cyclodextrin/citrox|mouthrinse with bãªta-cyclodextrin|citrox|mouthrinse without bãªta-cyclodextrin,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review/Clinical Trial Protocol|Letter"
NCT04364802,2020-04-29,2021-05-31,Interventional,COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients,Recruiting,Phase 2,University of Kentucky,NA,https://clinicaltrials.gov/ct2/show/NCT04364802,1,0,1,0,2,1,United States,0,povidone/iodine|gargle,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04373291,2020-05-18,2021-07-31,Interventional,Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic,"Active, not recruiting",Phase 3,Bandim Health Project,NA,https://clinicaltrials.gov/ct2/show/NCT04373291,1,0,1,1,4,0,Denmark,0,bcg-denmark|saline,Clinical Trial Protocol|Letter
NCT04367129,2020-04-14,2020-12-01,Observational,Electrocardiogram Analysis in COVID-19 Patients,Recruiting,NA,University Hospital of Ferrara,NA,https://clinicaltrials.gov/ct2/show/NCT04367129,1,1,2,0,0,0,Italy,0,ecg,Journal Article|Multicenter Study/Journal Article|Comment
NCT04439084,2020-03-06,2021-06-30,Observational,COVID-19 in Patients With Chronic Liver Diseases,Enrolling by invitation,NA,Stanford University,NA,https://clinicaltrials.gov/ct2/show/NCT04439084,1,0,1,0,1,1,United States,0,prospective chart review,Journal Article
NCT04343261,2020-04-10,2020-07-23,Interventional,Convalescent Plasma in the Treatment of COVID 19,Completed,Phase 2,Saint Francis Care,NA,https://clinicaltrials.gov/ct2/show/NCT04343261,3,2,5,0,9,1,United States,1,convalescent plasma,"Journal Article/Journal Article/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review/Clinical Trial, Phase II|Journal Article/Journal Article"
NCT04335162,2020-02-28,2021-08-31,Observational,Cardiovascular Complications and COVID-19 (CovCardioVasc-Study),Recruiting,NA,Centre Hospitalier Universitaire de Nice,NA,https://clinicaltrials.gov/ct2/show/NCT04335162,1,0,1,0,4,0,France,0,"NA",Journal Article
NCT04321928,2020-04-01,2021-04-21,Interventional,Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary,Recruiting,N/A,University of Pecs,NA,https://clinicaltrials.gov/ct2/show/NCT04321928,1,0,1,0,2,0,Hungary,0,personalized health education|general health education,Clinical Trial Protocol|Journal Article
NCT04394416,2020-06-02,2022-06-01,Interventional,Trial of Imatinib for Hospitalized Adults With COVID-19,Recruiting,Phase 3,"University of Maryland, Baltimore",NA,https://clinicaltrials.gov/ct2/show/NCT04394416,2,0,2,0,1,1,United States,0,imatinib|placebo,"Letter|Research Support, N.I.H., Extramural/Clinical Trial Protocol|Letter"
NCT04329923,2020-04-09,2020-11-11,Interventional,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Terminated,Phase 2,University of Pennsylvania,"Cohort 1: slow accrual Cohort 2: Other studies showed no benefit Cohort 3: Study met
    pre-specificied futility analysis at planned second interim analysis",https://clinicaltrials.gov/ct2/show/NCT04329923,1,1,2,0,7,1,United States,1,hydroxychloroquine|placebo,Journal Article|Multicenter Study|Randomized Controlled Trial/Journal Article|Multicenter Study|Randomized Controlled Trial
NCT04377815,2020-04-23,2020-05-14,Observational,Finding Out if COVID-19 Infection Can be pREdicted by ChAnges in Smell and/or Taste,Completed,NA,"University College, London",NA,https://clinicaltrials.gov/ct2/show/NCT04377815,1,0,1,0,1,0,United Kingdom,0,general public cohort,"Journal Article|Observational Study|Research Support, Non-U.S. Gov't"
NCT04352764,2020-03-27,2020-12-31,Observational [Patient Registry],ANTIBODY BASED TESTS FOR SARSCoV-2 COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings,Recruiting,NA,Texas Cardiac Arrhythmia Research Foundation,NA,https://clinicaltrials.gov/ct2/show/NCT04352764,1,0,1,0,2,1,United States,0,igm/igg rapid test|igg antibody test|igm,Journal Article
NCT04333420,2020-03-31,2021-05-31,Interventional,"Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia",Recruiting,Phase 2/Phase 3,InflaRx GmbH,NA,https://clinicaltrials.gov/ct2/show/NCT04333420,1,0,1,0,5,0,Germany|Netherlands,0,soc / ifx-1|soc / placebo|standard care|ifx-1|placebo,Journal Article
NCT04384926,2020-03-30,2020-12-31,Observational,Outcomes of Elective Cancer Surgery During the COVID-19 Pandemic Crisis,Recruiting,NA,University of Birmingham,NA,https://clinicaltrials.gov/ct2/show/NCT04384926,1,0,1,0,0,0,Spain,0,elective cancer surgery,"Comparative Study|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't"
NCT04358029,2020-04-09,2021-05-31,Observational,Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19),Recruiting,NA,Icahn School of Medicine at Mount Sinai,NA,https://clinicaltrials.gov/ct2/show/NCT04358029,1,0,1,0,1,1,United States,0,"NA",Comparative Study|Journal Article
NCT04323839,2020-03-20,2024-03-31,Observational [Patient Registry],COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY),Enrolling by invitation,NA,"University of California, San Francisco",NA,https://clinicaltrials.gov/ct2/show/NCT04323839,1,0,1,0,4,1,United States,0,pregnant women under investigation for coronavirus/diagnosed with covid-19|postpartum women under investigation for coronavirus/diagnosed with covid-19|pregnant women under investigation for coronavirus|diagnosed with covid-19|postpartum,"Journal Article|Observational Study|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04317092,2020-03-19,2020-12-19,Interventional,Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),"Active, not recruiting",Phase 2,"National Cancer Institute, Naples",NA,https://clinicaltrials.gov/ct2/show/NCT04317092,3,0,3,0,3,0,Italy,0,tocilizumab,"Clinical Trial Protocol|Journal Article/Journal Article/Clinical Trial, Phase II|Journal Article|Multicenter Study"
NCT04307459,2020-03-19,2020-09-01,Observational,Acute Respiratory Failure and COVID-19 in Real Life,Recruiting,NA,University of Milan,NA,https://clinicaltrials.gov/ct2/show/NCT04307459,1,0,1,0,3,0,Italy,0,SOP,Journal Article|Multicenter Study|Observational Study
NCT04441424,2020-04-03,2020-06-01,Interventional,Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients,Completed,N/A,Alkarkh Health Directorate-Baghdad,NA,https://clinicaltrials.gov/ct2/show/NCT04441424,1,0,1,0,1,0,Iraq,0,convalescent plasma|hydroxychloroquine / azithromycin,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04357106,2020-04-13,2020-07-31,Interventional,COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma,Recruiting,Phase 2,Centro de HematologÃ­a y Medicina Interna,NA,https://clinicaltrials.gov/ct2/show/NCT04357106,1,0,1,0,0,0,Mexico,0,convalescent plasma,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04340050,2020-04-10,2020-12-23,Interventional,COVID-19 Convalescent Plasma,Completed,Early Phase 1,University of Chicago,NA,https://clinicaltrials.gov/ct2/show/NCT04340050,1,0,1,0,4,1,United States,0,convalescent plasma,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04342182,2020-04-08,2021-07-01,Interventional,Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study),"Active, not recruiting",Phase 2/Phase 3,Erasmus Medical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04342182,1,0,1,0,11,0,Netherlands,0,convalescent plasma,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04507282,2020-05-15,2020-07-01,Observational,Eosinophil and Anticoagulation in COVID-19 Patients,Completed,NA,Bursa Postgraduate Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04507282,1,0,1,0,1,0,Turkey,0,lmwh,Journal Article
NCT04555096,2020-09-09,2021-11-30,Interventional,A Trial of GC4419 in Patients With Critical Illness Due to COVID-19,Recruiting,Phase 2,"Galera Therapeutics, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04555096,1,0,1,0,3,1,United States,0,gc4419|placebo,Journal Article
NCT04356495,2020-07-29,2021-08-15,Interventional,Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation,Recruiting,Phase 2/Phase 3,"University Hospital, Bordeaux",NA,https://clinicaltrials.gov/ct2/show/NCT04356495,1,0,1,0,6,0,France,0,vitamins|telmisartan|ciclesonide|interferon î²-1b,"Clinical Trial, Phase III|Letter|Randomized Controlled Trial"
NCT04445467,2020-08-01,2020-11-30,Interventional,An Adaptive Clinical Trial of Antivirals for COVID-19 Infection,Recruiting,Phase 2,Bayside Health,NA,https://clinicaltrials.gov/ct2/show/NCT04445467,1,0,1,0,1,0,Australia,0,favipiravir,"Clinical Trial, Phase II|Letter|Multicenter Study|Randomized Controlled Trial"
NCT04314232,2020-03-18,2021-12-31,Observational,Mechanisms for Covid-19 Disease Complications,Recruiting,NA,"University Hospital, Akershus",NA,https://clinicaltrials.gov/ct2/show/NCT04314232,1,0,1,0,1,0,Norway,0,"NA",Journal Article
NCT04448717,2020-06-16,2021-03-31,Observational,Longitudinal Study of Seroprevalence of SARS-CoV-2 Antibodies and Development of Immunity in School Children,Recruiting,NA,University of Zurich,NA,https://clinicaltrials.gov/ct2/show/NCT04448717,1,0,1,0,1,0,Switzerland,0,covid-19 antibody testing,Journal Article
NCT04343963,2020-04-04,2020-09-30,Interventional,Pyridostigmine in Severe SARS-CoV-2 Infection,Recruiting,Phase 2/Phase 3,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicaltrials.gov/ct2/show/NCT04343963,1,0,1,0,2,0,Mexico,0,pyridostigmine bromide|placebo,Clinical Trial Protocol|Journal Article
NCT04423770,2020-06-08,2021-06-08,Observational,COVID-19 Related Health and Infection Control Practices Among Dentists,"Active, not recruiting",NA,American Dental Association,NA,https://clinicaltrials.gov/ct2/show/NCT04423770,1,0,1,0,3,1,United States,0,no intervention,Journal Article
NCT04323592,2020-03-23,2020-05-10,Observational [Patient Registry],Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Completed,NA,University of Trieste,NA,https://clinicaltrials.gov/ct2/show/NCT04323592,1,0,1,0,6,0,Italy,1,methylprednisolone|standard care,Journal Article
NCT04411459,2020-02-01,2020-06-30,Observational,Risk Factors for Prolonged Invasive Mechanical Ventilation in COVID-19 Acute Respiratory Distress Syndrome,Completed,NA,Azienda Usl di Bologna,NA,https://clinicaltrials.gov/ct2/show/NCT04411459,2,3,5,0,2,0,Italy,0,invasive mechanical ventilation,"Journal Article/Journal Article/Journal Article|Multicenter Study|Research Support, N.I.H., Extramural/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, N.I.H., Extramural"
NCT04346355,2020-03-31,2020-06-06,Interventional,Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Terminated,Phase 2,Azienda UnitÃ  Sanitaria Locale Reggio Emilia,Based on interim analysis for futility and given an enrolment rate almost nil,https://clinicaltrials.gov/ct2/show/NCT04346355,1,0,1,0,2,0,Italy,0,tocilizumab,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04331808,2020-03-30,2021-03-31,Interventional,CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),"Active, not recruiting",Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicaltrials.gov/ct2/show/NCT04331808,1,0,1,0,2,0,France,0,tocilizumab,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04436276,2020-07-15,2021-12-03,Interventional,A Study of Ad26.COV2.S in Adults (COVID-19),Recruiting,Phase 1/Phase 2,Janssen Vaccines & Prevention B.V.,NA,https://clinicaltrials.gov/ct2/show/NCT04436276,2,0,2,0,7,1,United States|Belgium,0,ad26.cov2.s|placebo,Journal Article/Journal Article
NCT04356937,2020-04-20,2020-07-13,Interventional,Efficacy of Tocilizumab on Patients With COVID-19,Completed,Phase 3,Massachusetts General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04356937,1,0,1,0,4,1,United States,0,tocilizumab|placebo,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04416100,2020-04-29,2022-04-28,Observational,Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection (COVID-19),Recruiting,NA,Medical University Innsbruck,NA,https://clinicaltrials.gov/ct2/show/NCT04416100,1,0,1,0,1,0,Austria,0,pulmonary function tests|imaging|blood sample,Journal Article|Multicenter Study|Observational Study
NCT04282135,2020-02-15,2020-05-08,Observational,Detection of Influenza or SARS-CoV-2 Infection by IMS of Nasal Air Sampling,Completed,NA,Klinikum Bayreuth GmbH,NA,https://clinicaltrials.gov/ct2/show/NCT04282135,1,0,1,0,1,0,Germany,0,mcc ims,Evaluation Study|Journal Article
NCT04374526,2020-05-27,2021-04-30,Interventional,Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.,Recruiting,Phase 2/Phase 3,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,NA,https://clinicaltrials.gov/ct2/show/NCT04374526,1,0,1,0,2,0,Italy,0,convalescent plasma,"Clinical Trial, Phase II|Clinical Trial, Phase III|Comparative Study|Letter|Randomized Controlled Trial"
NCT04290780,2020-03-09,2021-12-31,Observational,COVID-19 - Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus,Recruiting,NA,Hospices Civils de Lyon,NA,https://clinicaltrials.gov/ct2/show/NCT04290780,1,0,1,0,6,0,France,0,nosocomial|hospital acquired infection,Journal Article|Multicenter Study|Observational Study
NCT04403477,2020-05-20,2020-07-20,Interventional,Convalescent Plasma Therapy in Severe COVID-19 Infection,Recruiting,Phase 2,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",NA,https://clinicaltrials.gov/ct2/show/NCT04403477,1,0,1,0,0,0,Bangladesh,0,convalescent plasma,"Clinical Trial, Phase II|Letter|Multicenter Study|Randomized Controlled Trial"
NCT04389840,2020-06-03,2021-02-28,Interventional,Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure,Recruiting,Phase 2/Phase 3,Chimerix,NA,https://clinicaltrials.gov/ct2/show/NCT04389840,1,0,1,0,10,1,United States,0,dociparastat sodium|placebo,Journal Article
NCT04344197,2020-04-02,2020-04-08,Observational,"Surgery During Covid-19: The Role of Asymptomatic Patients, a Survey",Completed,NA,University of Rome Tor Vergata,NA,https://clinicaltrials.gov/ct2/show/NCT04344197,1,0,1,0,1,0,Italy,0,global survey,Journal Article
NCT04328493,2020-04-07,2021-04-01,Interventional,The Vietnam Chloroquine Treatment on COVID-19,Recruiting,Phase 2,"Oxford University Clinical Research Unit, Vietnam",NA,https://clinicaltrials.gov/ct2/show/NCT04328493,1,0,1,0,3,0,Vietnam,0,chloroquine,Journal Article
NCT04427501,2019-11-17,2020-09-20,Interventional,A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness,Recruiting,Phase 2/Phase 3,Eli Lilly and Company,NA,https://clinicaltrials.gov/ct2/show/NCT04427501,2,0,2,0,31,1,United States|Puerto Rico,0,ly3819253|ly3832479|placebo,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article"
NCT04407156,2020-06-01,2020-06-07,Observational,Epidemiology of Acute Kidney Injury in COVID19 Disease in United Kingdom,Completed,NA,University Hospitals of Derby and Burton NHS Foundation Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04407156,1,0,1,0,2,0,United Kingdom,0,acute kidney injury,Journal Article
NCT04392973,2020-05-21,2021-11-30,Interventional,FAvipiravir and HydroxyChloroquine Combination Therapy,Recruiting,N/A,King Abdullah International Medical Research Center,NA,https://clinicaltrials.gov/ct2/show/NCT04392973,1,0,1,0,2,0,Saudi Arabia,0,favipiravir/hydroxychloroquine|favipiravir|hydroxychloroquine,Clinical Trial Protocol|Letter
NCT04521309,2020-06-19,2021-01-31,Interventional,SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients,Recruiting,Phase 1,Dow University of Health Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04521309,1,0,1,0,2,0,Pakistan,0,sars-cov-2 antibody based ivig therapy,Clinical Trial Protocol|Letter
NCT04336345,2020-04-01,2020-04-30,Observational [Patient Registry],Outcomes of Patients With COVID-19 in the Intensive Care Unit,Completed,NA,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicaltrials.gov/ct2/show/NCT04336345,1,0,1,0,6,0,Mexico,0,"NA",Journal Article|Multicenter Study|Observational Study
NCT04492475,2020-08-04,2020-12-15,Interventional,Adaptive COVID-19 Treatment Trial 3 (ACTT-3),"Active, not recruiting",Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicaltrials.gov/ct2/show/NCT04492475,1,0,1,0,28,1,"United States|Japan|Korea, Republic of|Mexico|Singapore",0,interferon|placebo|remdesivir,Journal Article|Review
NCT04401579,2020-05-08,2020-07-31,Interventional,Adaptive COVID-19 Treatment Trial 2 (ACTT-2),Completed,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicaltrials.gov/ct2/show/NCT04401579,2,0,2,0,13,1,"United States|Denmark|Japan|Korea, Republic of|Mexico|Singapore|Spain|United Kingdom",0,placebo|remdesivir|baricitinib,Journal Article|Review/Journal Article
NCT04349202,2020-04-10,2021-06-30,Observational,Beaumont Health Large-scale Automated Serologic Testing for COVID-19,Recruiting,NA,William Beaumont Hospitals,NA,https://clinicaltrials.gov/ct2/show/NCT04349202,1,0,1,0,2,1,United States,0,euroimmun assay,Journal Article
NCT04557605,2020-09-14,2020-10-15,Interventional,Effects of a Face Mask on Oxygenation During Exercise,Completed,N/A,University of Saskatchewan,NA,https://clinicaltrials.gov/ct2/show/NCT04557605,1,0,1,0,1,0,Canada,0,progressive cycling exercise test to exhaustion,Journal Article|Randomized Controlled Trial
NCT04351152,2020-05-05,2021-03-31,Interventional,Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19,Recruiting,Phase 3,"Humanigen, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04351152,1,0,1,0,10,1,United States|Brazil,0,lenzilumab|standard care,"Journal Article|Multicenter Study|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04428099,2020-01-13,2022-01-12,Interventional,Healthy Lifestyle Promotion as Adjunctive Teletherapy for Treatment-resistant Major Depression,Recruiting,N/A,University of the Balearic Islands,NA,https://clinicaltrials.gov/ct2/show/NCT04428099,1,0,1,0,0,0,Spain,0,lifestyle change promotion program|mindfulness|information,Clinical Trial Protocol|Journal Article
NCT04412538,2020-05-15,2020-09-30,Interventional,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19,Recruiting,Phase 1/Phase 2,Chinese Academy of Medical Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04412538,1,0,1,1,1,0,China,0,inactivated sars-cov-2 vaccine|medium dosage inactivated sars-cov-2 vaccine on a 0-/28-day schedule|medium dosage inactivated sars-cov-2 vaccine on a 0-/14-day schedule|placebo|28-day schedule|14-day schedule|medium dosage inactivated sars-cov-2 vaccine on a 0-,Journal Article
NCT04346342,2020-03-06,2020-09-01,Observational,PRactice of VENTilation in COVID-19 Patients (PRoVENT-COVID),Completed,NA,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),NA,https://clinicaltrials.gov/ct2/show/NCT04346342,2,0,2,0,3,0,Netherlands,0,"NA",Journal Article/Journal Article
NCT04486404,2020-04-01,2020-06-30,Observational,"Needs, Perceptions and Acute Stress of Healtcare Workers Caring for COVID-19 Patients in South America",Enrolling by invitation,NA,Universidad Miguel Hernandez de Elche,NA,https://clinicaltrials.gov/ct2/show/NCT04486404,1,0,1,0,3,0,Argentina|Chile|Colombia|Ecuador|Spain,0,online survey,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04366882,2020-04-14,2020-12-31,Interventional,Minimal Invasive Autopsies to Investigate Changes in Deceased COVID-19 Patients,Recruiting,N/A,Jessa Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04366882,1,0,1,0,0,0,Belgium,0,ct-scan,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04487990,2020-06-29,2020-12-31,Interventional,CoV-Hep Study: Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19,Recruiting,N/A,University of Sao Paulo General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04487990,1,0,1,0,0,0,Brazil,0,heparin,Clinical Trial Protocol|Letter
NCT04395144,2020-05-15,2021-03-30,Interventional,COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss,Recruiting,N/A,HÃ´pital de Verdun,NA,https://clinicaltrials.gov/ct2/show/NCT04395144,1,0,1,0,2,0,Canada,0,prone positioning|standard care,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04347941,2020-07-11,2021-06-11,Interventional,Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE,Recruiting,N/A,University College Hospital Galway,NA,https://clinicaltrials.gov/ct2/show/NCT04347941,1,0,1,0,1,0,Ireland,0,prone positioning|standard care,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04391140,2020-05-13,2020-12-31,Interventional,Prone Positioning and High-flow Nasal Cannula in COVID-19 Induced ARDS,Recruiting,N/A,Hospital Universitari Vall d'Hebron Research Institute,NA,https://clinicaltrials.gov/ct2/show/NCT04391140,1,0,1,0,2,0,Spain,0,prone positioning,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04358939,2020-04-27,2021-11-10,Interventional,Prone Position in Patients on High-flow Nasal Oxygen Therapy for COVID-19 (HIGH-PRONE-COVID-19),Recruiting,N/A,"University Hospital, Tours",NA,https://clinicaltrials.gov/ct2/show/NCT04358939,1,0,1,0,7,0,France,0,prone positioning,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04386395,2020-03-30,2020-05-01,Observational,Immune Changes in Severe COVID-19 Pulmonary Infections,"Active, not recruiting",NA,"Central Hospital, Nancy, France",NA,https://clinicaltrials.gov/ct2/show/NCT04386395,1,0,1,0,0,0,France,0,"NA",Clinical Trial|Journal Article
NCT04342663,2020-04-10,2020-08-20,Interventional,"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection",Completed,Phase 2,Washington University School of Medicine,NA,https://clinicaltrials.gov/ct2/show/NCT04342663,2,0,2,0,5,1,United States,0,fluvoxamine|placebo,"Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article|Review"
NCT04412655,2020-05-05,2020-05-30,Observational,Primary Angioplasty for STEMI During COVID-19 Pandemic (ISACS-STEMI COVID-19) Registry,"Active, not recruiting",NA,"UniversitÃ  degli Studi del Piemonte Orientale ""Amedeo Avogadro""",NA,https://clinicaltrials.gov/ct2/show/NCT04412655,2,0,2,0,1,0,Italy,0,percutaneous coronary revascularization for stemi,"Journal Article|Multicenter Study/Comparative Study|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't"
NCT04364022,2020-04-23,2021-03-31,Interventional,Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland,Recruiting,Phase 3,"University Hospital, Geneva",NA,https://clinicaltrials.gov/ct2/show/NCT04364022,1,0,1,0,1,0,Switzerland,0,lopinavir/ritonavir|lopinavir|ritonavir,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04435041,2020-06-01,2021-05-31,Observational [Patient Registry],Remote-by-Default Care in the COVID-19 Pandemic,"Active, not recruiting",NA,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04435041,2,0,2,0,0,0,United Kingdom,0,"NA","Journal Article|Research Support, Non-U.S. Gov't/Journal Article"
NCT04459247,2020-06-15,2020-08-30,Interventional,"Short Term, High Dose Vitamin D Supplementation for COVID-19","Active, not recruiting",N/A,Postgraduate Institute of Medical Education and Research,NA,https://clinicaltrials.gov/ct2/show/NCT04459247,1,0,1,0,1,0,India,0,vitamin d,Journal Article
NCT04374149,2020-04-30,2020-09-25,Interventional,Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS,"Active, not recruiting",Phase 2,Prisma Health-Upstate,NA,https://clinicaltrials.gov/ct2/show/NCT04374149,1,0,1,0,1,1,United States,0,therapeutic plasma exchange (tpe)|ruxolitinib,"Clinical Trial|Journal Article|Research Support, Non-U.S. Gov't"
NCT04487964,2020-01-01,2020-12-01,Interventional,Complementary Intervention for COVID-19,Recruiting,N/A,Egyptian Biomedical Research Network,NA,https://clinicaltrials.gov/ct2/show/NCT04487964,1,0,1,0,1,0,Egypt,0,licorice extract,Journal Article
NCT04468893,2020-05-20,2020-12-31,Interventional,Online Positive Psychology Intervention for Depression and Anxiety Due to COVID-19,Recruiting,N/A,Universidad Internacional de Valencia,NA,https://clinicaltrials.gov/ct2/show/NCT04468893,1,5,6,0,1,0,Mexico,0,online intervention mental health covid-19,Journal Article/Journal Article
NCT04455360,2020-10-01,2021-03-31,Interventional,Early EMDR Following Covid-19 Critical Illness: A Feasibility Trial,Recruiting,N/A,University Hospital Southampton NHS Foundation Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04455360,1,0,1,0,1,0,United Kingdom,0,eye movement desensitisation/reprocessing recent traumatic event protocol|eye movement desensitisation|reprocessing recent traumatic event protocol,Clinical Trial Protocol|Letter
NCT04328467,2020-04-06,2020-08-31,Interventional,Pre-exposure Prophylaxis for SARS-Coronavirus-2,"Active, not recruiting",Phase 3,University of Minnesota,NA,https://clinicaltrials.gov/ct2/show/NCT04328467,1,0,1,0,5,1,United States,0,hydroxychloroquine|placebo,Journal Article
NCT04341922,2020-05-09,2020-08-20,Interventional,A Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic,"Active, not recruiting",N/A,Karolinska Institutet,NA,https://clinicaltrials.gov/ct2/show/NCT04341922,1,0,1,0,5,0,Sweden,0,internet-delivered cognitive behavior therapy (icbt) for dysfunctional worry related to the covid-19 pandemic,Journal Article
NCT04382755,2020-05-22,2021-02-28,Interventional,ZilucoplanÂ® in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure,"Active, not recruiting",Phase 2,"University Hospital, Ghent",NA,https://clinicaltrials.gov/ct2/show/NCT04382755,1,0,1,0,2,0,Belgium,0,placebo|zilucoplanâ®,"Clinical Trial, Phase II|Letter|Multicenter Study|Randomized Controlled Trial"
NCT04352608,2020-04-16,2020-07-10,Interventional,Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19),"Active, not recruiting",Phase 1/Phase 2,"Sinovac Biotech Co., Ltd",NA,https://clinicaltrials.gov/ct2/show/NCT04352608,1,0,1,1,3,0,China,0,placebo|inactivated sars-cov-2 vaccine,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04400838,2020-05-28,2021-09-30,Interventional,Investigating a Vaccine Against COVID-19,Recruiting,Phase 2/Phase 3,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04400838,2,0,2,1,9,0,United Kingdom,0,chadox1|menacwy|menacwy vaccine|two dose menacwy vaccine min. 4 weeks apart|two dose chadox1 ncov-19/covishield 0.5ml|two dose chadox1 ncov-19/covishield 0.25ml/0.5ml|2.2x10^10vp (qpcr) boost|boost|two dose chadox1 ncov-19|covishield 0.5ml|covishield 0.25ml|0.5ml,"Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04406090,2020-04-01,2020-06-30,Observational,Endovascular Thrombectomy in COVID-19 Infected Patients,Completed,NA,"University Hospital, Montpellier",NA,https://clinicaltrials.gov/ct2/show/NCT04406090,1,0,1,0,1,0,France,0,mechanical trombectomy,Journal Article|Multicenter Study
NCT04412304,2020-03-06,2020-04-30,Observational,Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients,Completed,NA,Karolinska Institutet,NA,https://clinicaltrials.gov/ct2/show/NCT04412304,1,0,1,0,2,0,Sweden,0,tinzaparin/dalteparin|tinzaparin|dalteparin,Journal Article
NCT04449380,2020-11-02,2021-04-30,Interventional,Clinical Study for the Treatment With Interferon-ÃŸ-1a (IFNÃŸ-1a) of COVID-19 Patients,Recruiting,Phase 2,IRCCS San Raffaele,NA,https://clinicaltrials.gov/ct2/show/NCT04449380,1,0,1,0,4,0,Italy,0,interferon-ãÿ-1a|standard care,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial"
NCT04495816,2020-07-15,2021-04-30,Interventional,COVID-19 Anosmia Study,Recruiting,Phase 2,Icahn School of Medicine at Mount Sinai,NA,https://clinicaltrials.gov/ct2/show/NCT04495816,1,0,1,0,2,1,United States,0,omega-3|placebo/control|placebo|control,Letter|Randomized Controlled Trial
NCT04477655,2020-05-03,2020-11-30,Interventional,Prone Positioning in Non-intubated Patients With COVID-19 Associated Acute Respiratory Failure,Recruiting,N/A,Hospital Civil de Guadalajara,NA,https://clinicaltrials.gov/ct2/show/NCT04477655,1,0,1,0,2,0,Mexico,0,prone positioning|oxygen,Letter|Randomized Controlled Trial
NCT04438070,2020-04-10,2020-06-30,Interventional,COVID Screening Strategies in Homeless Shelters,Recruiting,N/A,St. Joseph's Healthcare Hamilton,NA,https://clinicaltrials.gov/ct2/show/NCT04438070,1,0,1,0,0,0,Canada,0,covid-19 swab,Comparative Study|Letter|Randomized Controlled Trial
NCT04357535,2020-05-10,2020-07-01,Observational,Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives,Completed,NA,King Faisal Specialist Hospital & Research Center,NA,https://clinicaltrials.gov/ct2/show/NCT04357535,1,0,1,0,8,0,Saudi Arabia,0,angiotensin-converting enzyme inhibitors (ace-i)/angiotensin ii receptor blockers (arb)|ace inhibitor|arb blocker,Journal Article
NCT04383535,2020-05-15,2020-09-27,Interventional,Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia,Completed,N/A,Hospital Italiano de Buenos Aires,NA,https://clinicaltrials.gov/ct2/show/NCT04383535,1,1,2,0,4,0,Argentina,0,convalescent plasma|placebo,Journal Article
NCT04529525,2020-08-19,2020-12-31,Interventional,Ivermectin to Prevent Hospitalizations in COVID-19,Recruiting,Phase 2/Phase 3,Instituto de CardiologÃ­a de Corrientes,NA,https://clinicaltrials.gov/ct2/show/NCT04529525,1,11,12,0,3,0,Argentina,0,ivermectin|placebo,Letter|Randomized Controlled Trial
NCT04341142,2020-04-09,2023-04-09,Interventional,Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER,Recruiting,N/A,Hospices Civils de Lyon,NA,https://clinicaltrials.gov/ct2/show/NCT04341142,1,0,1,0,5,0,France,0,serology test,Clinical Study|Journal Article|Multicenter Study
NCT04380987,2020-05-04,2021-07-31,Observational,Luxembourg Cohort of Positive Patients for COVID-19: a Stratification Study to Predict Patient Prognosis,Recruiting,NA,Luxembourg Institute of Health,NA,https://clinicaltrials.gov/ct2/show/NCT04380987,1,0,1,0,0,0,Luxembourg,0,biological samples,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04344119,2020-04-09,2021-04-30,Observational,Assessment of Chilbains Occuring During Covid-19 Infection,Recruiting,NA,Centre Hospitalier Universitaire de Nice,NA,https://clinicaltrials.gov/ct2/show/NCT04344119,1,0,1,0,2,0,France,0,"NA",Journal Article
NCT04430608,2020-05-25,2021-04-25,Interventional,Remote Continues Glucose Monitoring During the COVID-19 Pandemic in Quarantined Hospitalized Patients,Recruiting,N/A,Nordsjaellands Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04430608,1,0,1,0,0,0,Denmark,0,dexcom,Letter|Randomized Controlled Trial
NCT04348695,2020-04-12,2020-05-13,Interventional,Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.,Recruiting,Phase 2,FundaciÃ³n de investigaciÃ³n HM,NA,https://clinicaltrials.gov/ct2/show/NCT04348695,1,0,1,0,1,0,Spain,0,ruxolitinib|standard care|simvastatin,Journal Article|Review
NCT04359329,2020-04-20,2020-11-15,Interventional,Estrogen Patch for COVID-19 Symptoms,Recruiting,Phase 2,Stony Brook University,NA,https://clinicaltrials.gov/ct2/show/NCT04359329,1,0,1,0,0,1,United States,0,estradiol,Journal Article|Review
NCT04244591,2020-01-26,2020-04-13,Interventional,Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure,Completed,Phase 2/Phase 3,Peking Union Medical College Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04244591,1,0,1,0,6,0,China,0,methylprednisolone|standard care,Journal Article|Review
NCT04304313,2020-02-09,2020-03-01,Interventional,A Pilot Study of Sildenafil in COVID-19,Recruiting,Phase 3,Tongji Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04304313,1,0,1,0,1,0,China,0,sildenafil citrate,Journal Article|Review
NCT04321174,2020-04-17,2021-03-31,Interventional,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,Recruiting,Phase 3,"St. Michael's Hospital, Toronto",NA,https://clinicaltrials.gov/ct2/show/NCT04321174,1,0,1,0,1,0,Canada,0,lopinavir/ritonavir|lopinavir|ritonavir,Journal Article|Review
NCT04429854,2020-05-02,2021-11-02,Interventional,Donated Antibodies Working Against nCoV,Recruiting,Phase 2,Universitaire Ziekenhuizen Leuven,NA,https://clinicaltrials.gov/ct2/show/NCT04429854,1,0,1,0,0,0,Belgium,0,convalescent plasma|standard care,"Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial"
NCT04447534,2020-06-23,2030-10-01,Interventional,Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19,Recruiting,Phase 3,Tanta University,NA,https://clinicaltrials.gov/ct2/show/NCT04447534,1,0,1,0,3,0,Egypt,0,chloroquine|zinc,Journal Article
NCT04444661,2020-06-10,2020-11-11,Observational,Effects of COVID-19 Induced Deconditioning After Long-term High Intensity Resistance Exercise,"Active, not recruiting",NA,University of Erlangen-NÃ¼rnberg Medical School,NA,https://clinicaltrials.gov/ct2/show/NCT04444661,1,0,1,0,3,0,Germany,0,"NA",Journal Article
NCT04349592,2020-04-14,2020-08-14,Interventional,Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19,Recruiting,N/A,Hamad Medical Corporation,NA,https://clinicaltrials.gov/ct2/show/NCT04349592,1,0,1,0,1,0,Qatar,0,hydroxychloroquine|azithromycin|placebo,Journal Article
NCT04386083,2020-06-10,2020-12-31,Observational,Neurologic Manifestations of COVID-19,Recruiting,NA,University of the Philippines,NA,https://clinicaltrials.gov/ct2/show/NCT04386083,1,0,1,0,1,0,Philippines,0,"NA","Journal Article|Research Support, Non-U.S. Gov't"
NCT04361877,2020-03-30,2020-04-20,Observational,Cardiovascular Prevention During COVID-19 Pandemic Lockdown in Young Adults (COLA Trial),Recruiting,NA,Klinikum der Universitaet Muenchen,NA,https://clinicaltrials.gov/ct2/show/NCT04361877,1,0,1,0,1,0,Germany,0,"NA",Journal Article
NCT04445324,2020-08-25,2020-08-25,Interventional,Effects of Online and Recovery-oriented Peer Support Groups Facilitated by Peer Support Workers in Times of COVID-19,"Active, not recruiting",N/A,Centre de Recherche de l'Institut Universitaire en santÃ© Mentale de MontrÃ©al,NA,https://clinicaltrials.gov/ct2/show/NCT04445324,1,0,1,0,4,0,Canada,0,"online support group|control|or psychotherapy, n=10)",Journal Article
NCT04405726,2020-03-27,2022-03-31,Observational,Prognostic Factors of COVID19,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicaltrials.gov/ct2/show/NCT04405726,1,0,1,0,2,0,France,0,"NA",Journal Article
NCT04402970,2020-06-19,2020-12-31,Interventional,Dornase Alfa for ARDS in Patients With SARS-CoV-2,Completed,Phase 3,University of Missouri-Columbia,NA,https://clinicaltrials.gov/ct2/show/NCT04402970,1,0,1,0,3,1,United States,0,dornase alfa,Journal Article
NCT04402944,2020-07-05,2021-05-31,Interventional,Pulmozyme to Improve COVID-19 ARDS Outcomes,Recruiting,Phase 2,Boston Children's Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04402944,1,0,1,0,2,1,United States,0,pulmozyme|placebo,Journal Article
NCT04541979,2020-06-04,2020-11-01,Interventional,Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19,Recruiting,Phase 2,Region Skane,NA,https://clinicaltrials.gov/ct2/show/NCT04541979,1,0,1,0,0,0,Sweden,0,aerosolized dnase|sodium,Journal Article
NCT04445285,2020-04-28,2020-11-30,Interventional,Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure,Recruiting,Phase 2,University of South Alabama,NA,https://clinicaltrials.gov/ct2/show/NCT04445285,1,0,1,0,2,1,United States,0,pulmozyme/ recombinant human deoxyribonuclease (rh-dnase)|saline|pulmozyme|rh-dnase,Journal Article
NCT04432987,2020-05-25,2020-08-25,Interventional,Dornase Alpha for the Treatment of COVID-19,Recruiting,Phase 2,Acibadem University,NA,https://clinicaltrials.gov/ct2/show/NCT04432987,1,0,1,0,0,0,Turkey,0,pulmozyme,Journal Article
NCT04343053,2020-04-08,2020-06-09,Interventional,Pro-thrombotic Status in Patients With SARS-Cov-2 Infection,"Active, not recruiting",N/A,University Hospital of Ferrara,NA,https://clinicaltrials.gov/ct2/show/NCT04343053,1,0,1,0,2,0,Italy,0,sars-cov-2 infection,Journal Article
NCT04395807,2020-06-03,2020-12-31,Interventional,Helmet CPAP Versus HFNC in COVID-19,Recruiting,N/A,Lund University,NA,https://clinicaltrials.gov/ct2/show/NCT04395807,1,0,1,0,1,0,Sweden,0,cpap|oxygen,Comparative Study|Journal Article|Randomized Controlled Trial
NCT04405739,2020-06-16,2021-02-12,Interventional,The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID),Recruiting,Phase 2,"Ridgeback Biotherapeutics, LP",NA,https://clinicaltrials.gov/ct2/show/NCT04405739,1,0,1,0,14,1,United States,0,eidd-2801|placebo,"Journal Article|Research Support, N.I.H., Extramural"
NCT04405570,2020-06-16,2021-01-30,Interventional,"A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19","Active, not recruiting",Phase 2,"Ridgeback Biotherapeutics, LP",NA,https://clinicaltrials.gov/ct2/show/NCT04405570,1,0,1,0,16,1,United States,0,eidd-2801|placebo,"Journal Article|Research Support, N.I.H., Extramural"
NCT04645563,2020-03-11,2020-05-30,Observational,Using Whatsapp for the Consultation,Completed,NA,Kafkas University,NA,https://clinicaltrials.gov/ct2/show/NCT04645563,1,0,1,0,0,0,Turkey,0,sending thorax ct video images via smartphone applications,Journal Article
NCT04558476,2020-09-01,2022-09-01,Interventional,Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation,Recruiting,Phase 2,University of Liege,NA,https://clinicaltrials.gov/ct2/show/NCT04558476,1,0,1,0,0,0,Belgium,0,convalescent plasma|standard care,Clinical Trial Protocol|Journal Article
NCT04304053,2020-03-18,2020-06-15,Interventional,Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention,Completed,Phase 3,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,https://clinicaltrials.gov/ct2/show/NCT04304053,1,0,1,0,9,0,Spain,0,treatment/prophylaxis|standard care|treatment|prophylaxis,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04476667,2020-06-15,2021-05-31,Interventional,"Online Delivery of Psychotherapy, Tailored to Patients' Suffering From Mental Health Problems Due to COVID-19",Recruiting,N/A,Queen's University,NA,https://clinicaltrials.gov/ct2/show/NCT04476667,1,0,1,0,0,0,Canada,0,psychotherapy,Journal Article
NCT04510623,2020-03-17,2021-06-30,Observational,Host Response Mediators in Coronavirus (COVID-19) Infection,Recruiting,NA,University of British Columbia,NA,https://clinicaltrials.gov/ct2/show/NCT04510623,1,0,1,0,0,0,Canada,0,ace/arb|standard care|arb|ace inhibitor,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04502108,2020-04-01,2022-12-31,Observational,Behavior During and After COVID-19 Crisis,Recruiting,NA,Bern University of Applied Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04502108,1,0,1,0,1,0,Switzerland,0,covid-19,Journal Article
NCT04369378,2020-08-19,2021-02-28,Interventional,Effectiveness of Using a Meditation App in Reducing Anxiety and Improving Well-being During the Covid-19 Pandemic,Recruiting,N/A,Lake Erie College of Osteopathic Medicine,NA,https://clinicaltrials.gov/ct2/show/NCT04369378,1,0,1,0,2,1,United States,0,meditation app usage,Letter|Randomized Controlled Trial
NCT04362059,2020-06-18,2021-07-27,Interventional,A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19,Recruiting,N/A,University Hospital Southampton NHS Foundation Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04362059,1,14,15,0,3,0,United Kingdom,0,covsurf drug delivery system|standard care,Letter|Randomized Controlled Trial
NCT04348929,2020-04-16,2021-08-16,Interventional,Birth Experience During COVID-19 Confinement,Recruiting,N/A,"Central Hospital, Nancy, France",NA,https://clinicaltrials.gov/ct2/show/NCT04348929,1,0,1,0,3,0,France,0,questionnaire,Comparative Study|Journal Article|Multicenter Study
NCT04351906,2020-05-03,2021-06-01,Interventional,Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome,Recruiting,N/A,University of Giessen,NA,https://clinicaltrials.gov/ct2/show/NCT04351906,1,1,2,0,5,0,Germany,0,ecco2r,Journal Article
NCT04444674,2020-06-24,2020-12-31,Interventional,COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection,"Active, not recruiting",Phase 1/Phase 2,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04444674,1,0,1,1,4,0,South Africa,0,chadox1|saline,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04315480,2020-03-12,2020-04-09,Interventional,Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis,"Active, not recruiting",Phase 2,UniversitÃ  Politecnica delle Marche,NA,https://clinicaltrials.gov/ct2/show/NCT04315480,1,0,1,0,2,0,Italy,0,tocilizumab,"Clinical Trial, Phase II|Journal Article|Multicenter Study"
NCT04444531,2020-03-20,2020-05-19,Observational,Ozone Therapy and Coronavirus Disease of 2019 (COVID-19) Pneumonia,Completed,NA,Institut d'InvestigaciÃ³ BiomÃ¨dica de Girona Dr. Josep Trueta,NA,https://clinicaltrials.gov/ct2/show/NCT04444531,1,0,1,0,3,0,Spain,0,"NA",Controlled Clinical Trial|Journal Article
NCT04369690,2020-04-03,2021-04-03,Observational,"The Psychological, Social, and Economic Impacts of COVID-19",Recruiting,NA,University of Ottawa,NA,https://clinicaltrials.gov/ct2/show/NCT04369690,1,0,1,0,0,0,Canada,0,"NA",Journal Article|Multicenter Study|Observational Study
NCT04555005,2020-03-10,2020-04-26,Interventional,Mindfulness-based Crisis Intervention for COVID-19 Frontline Healthcare Workers During COVID-19,Completed,N/A,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,NA,https://clinicaltrials.gov/ct2/show/NCT04555005,1,0,1,0,0,0,Spain,0,mindfulness,Journal Article
NCT04425629,2020-06-16,2021-04-10,Interventional,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19",Recruiting,Phase 2/Phase 3,Regeneron Pharmaceuticals,NA,https://clinicaltrials.gov/ct2/show/NCT04425629,1,0,1,0,16,1,United States|Romania,0,regn10933/regn10987 combination therapy|placebo|regn10933|regn10987,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04372186,2020-05-14,2020-08-18,Interventional,A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,"Active, not recruiting",Phase 3,"Genentech, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04372186,1,0,1,0,7,1,United States|Brazil|Kenya|Mexico|Peru|South Africa,0,placebo|tocilizumab,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04371419,2020-05-13,2020-05-24,Interventional,COVID-19 Health Messaging to Underserved Communities,Completed,N/A,"National Bureau of Economic Research, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04371419,1,0,1,0,2,1,United States,0,messaging,Journal Article
NCT04492904,2020-07-23,2021-03-31,Observational,Singapore COVID-19 Chemosensory Tracking (SCCT) Study,Recruiting,NA,"Clinical Nutrition Research Centre, Singapore",NA,https://clinicaltrials.gov/ct2/show/NCT04492904,1,0,1,0,0,0,Singapore,0,questionnaire|home-use test,Journal Article
NCT04501978,2020-08-04,2022-07-31,Interventional,ACTIV-3: Therapeutics for Inpatients With COVID-19,Recruiting,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicaltrials.gov/ct2/show/NCT04501978,1,0,1,0,21,1,United States|Denmark|Poland|Singapore|Spain|Switzerland,0,ly3819253|placebo|remdesivir|vir-7831|brii-196/brii-198|brii-196|brii-198,Journal Article
NCT04358380,2020-04-15,2020-12-31,Observational,Liver Injury in Patients With COVID-19,Enrolling by invitation,NA,"Austral University, Argentina",NA,https://clinicaltrials.gov/ct2/show/NCT04358380,1,0,1,0,2,0,Argentina,0,liver,Journal Article
NCT04344041,2020-04-15,2021-05-31,Interventional,COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),Recruiting,Phase 3,"University Hospital, Angers",NA,https://clinicaltrials.gov/ct2/show/NCT04344041,1,0,1,0,4,0,France,0,cholecalciferol,Journal Article|Multicenter Study|Randomized Controlled Trial
NCT04635241,2020-06-01,2021-04-01,Interventional,Inhaled Heparin for Hospitalised COVID-19 Patients,Recruiting,Phase 2/Phase 3,Australian National University,NA,https://clinicaltrials.gov/ct2/show/NCT04635241,1,0,1,0,1,0,Argentina|Egypt,0,heparin,Journal Article
NCT04470427,2020-07-27,2022-10-27,Interventional,"A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19","Active, not recruiting",Phase 3,"ModernaTX, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04470427,1,0,1,1,13,1,United States,0,mrna-1273|placebo,"Journal Article|Research Support, Non-U.S. Gov't|Research Support, N.I.H., Extramural"
NCT04540029,2020-05-06,2022-10-31,Observational,Measuring Outcomes of Maternal COVID-19-related Prenatal Exposure,Recruiting,NA,"IRCCS National Neurological Institute ""C. Mondino"" Foundation",NA,https://clinicaltrials.gov/ct2/show/NCT04540029,1,0,1,0,0,0,Italy,0,maternal stress,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04344327,2020-04-10,2020-04-21,Observational,Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Critical COVID-19 France CCF,Completed,NA,French Cardiology Society,NA,https://clinicaltrials.gov/ct2/show/NCT04344327,1,0,1,0,1,0,France,0,"NA",Journal Article
NCT04336410,2020-04-03,2022-01-31,Interventional,"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","Active, not recruiting",Phase 1,Inovio Pharmaceuticals,NA,https://clinicaltrials.gov/ct2/show/NCT04336410,1,0,1,1,8,1,United States,0,ino-4800|cellectraâ® 2000,Journal Article
NCT04382235,2020-03-26,2020-12-30,Observational,Non-invasive Ventilatory Support of Patients Affected by COVID-19,"Active, not recruiting",NA,University of Milano Bicocca,NA,https://clinicaltrials.gov/ct2/show/NCT04382235,1,0,1,0,1,0,Italy,0,non-invasive ventilatory support,Journal Article
NCT04549376,2020-07-01,2020-10-20,Interventional,Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo,Recruiting,Phase 2,"Pi Research Consultancy Center, Bangladesh",NA,https://clinicaltrials.gov/ct2/show/NCT04549376,1,0,1,0,0,0,Bangladesh,0,povidone-iodine|placebo,Clinical Trial Protocol|Letter
NCT04414631,2020-08-06,2021-06-30,Interventional,Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,Recruiting,Phase 2,"University Hospital, Basel, Switzerland",NA,https://clinicaltrials.gov/ct2/show/NCT04414631,1,0,1,0,4,0,Switzerland,0,conestat alfa,Clinical Trial Protocol|Letter
NCT04459286,2020-10-09,2021-03-31,Interventional,The Nitazoxanide Plus Atazanavir for COVID-19 Study,Recruiting,Phase 2,Obafemi Awolowo University,NA,https://clinicaltrials.gov/ct2/show/NCT04459286,1,0,1,0,3,0,Nigeria,0,nitazoxanide/atazanavir/ritonavir|standard care|nitazoxanide|atazanavir|ritonavir,Clinical Trial Protocol|Comparative Study|Letter
NCT04463706,2020-06-01,2021-06-30,Observational,COVID19 Severity Prediction and Health Services Research Evaluation,Recruiting,NA,Hospital Galdakao-Usansolo,NA,https://clinicaltrials.gov/ct2/show/NCT04463706,1,0,1,0,1,0,Spain,0,predictors adverse evolution|predictors of health care provide,Journal Article
NCT04345536,2020-03-15,2021-01-01,Observational [Patient Registry],Prospective Quality Register of Patients With Confirmed Covid-19 at Oslo University Hospital,Recruiting,NA,Oslo University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04345536,1,0,1,0,0,0,Norway,0,"NA",Journal Article
NCT04479163,2020-06-04,2020-10-25,Interventional,Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2,Completed,N/A,Fundacion Infant,NA,https://clinicaltrials.gov/ct2/show/NCT04479163,1,0,1,0,3,0,Argentina,0,convalescent plasma|placebo,Journal Article
NCT04615429,2020-09-15,2021-01-31,Interventional,Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19,Recruiting,Phase 2,Puerta de Hierro University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04615429,1,0,1,0,2,0,Spain,0,mesenchymal stem cells|placebo,Clinical Trial Protocol|Letter
NCT04422418,2020-07-01,2020-12-14,Observational,Impact of Burnout on Cardiovascular and Immune Biomarkers in Healthcare Professionals - Covid-19 Pandemic in Abu Dhabi,Recruiting,NA,Khalifa University for Science and Technology,NA,https://clinicaltrials.gov/ct2/show/NCT04422418,1,0,1,0,1,0,United Arab Emirates,0,"NA",Journal Article
NCT04385121,2020-04-16,2020-04-16,Observational,Psychological Impact of the Hospitalization of a Family Member in Intensive Care for Covid-19 Infection,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicaltrials.gov/ct2/show/NCT04385121,1,0,1,0,1,0,France,0,questionnaire,Journal Article
NCT04338009,2020-03-31,2020-12-31,Interventional,Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019,Enrolling by invitation,N/A,University of Pennsylvania,NA,https://clinicaltrials.gov/ct2/show/NCT04338009,1,0,1,0,2,1,United States,0,discontinuation of arb|continuation of arb|ace inhibitor,Journal Article
NCT04484493,2020-08-08,2020-10-25,Interventional,Corticosteroid Nasal Spray in COVID-19 Anosmia,Completed,Phase 3,Benha University,NA,https://clinicaltrials.gov/ct2/show/NCT04484493,1,0,1,0,5,0,Egypt,0,mometasone furoate nasal spray,Journal Article
NCT04438980,2020-05-15,2020-12-31,Interventional,Glucocorticoids in COVID-19 (CORTIVID),Recruiting,Phase 3,Fundacion Miguel Servet,NA,https://clinicaltrials.gov/ct2/show/NCT04438980,1,0,1,0,1,0,Spain,0,methylprednisolone|placebo,Clinical Trial Protocol|Letter
NCT04472728,2020-06-16,2021-07-31,Interventional,Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients,Recruiting,Phase 2/Phase 3,Biophytis,NA,https://clinicaltrials.gov/ct2/show/NCT04472728,1,0,1,0,5,1,United States|Belgium|Brazil|France|Puerto Rico,0,bio101|placebo,Clinical Trial Protocol|Letter
NCT04389645,2020-04-07,2020-05-12,Observational,Interferon Gamma Induced Protein 10 (IP-10) in a Clinical Decision Support Protocol in COVID-19 Patients,Completed,NA,MeMed Diagnostics Ltd.,NA,https://clinicaltrials.gov/ct2/show/NCT04389645,1,0,1,0,0,0,Israel,0,ip-10,Clinical Trial|Journal Article|Observational Study
NCT04458337,2020-03-13,2021-03-13,Observational,SURgical Outcomes in COvid Patients - the SUROCO Multicenter Cohort Study (COVID-19),Recruiting,NA,Centre hospitalier de l'UniversitÃ© de MontrÃ©al (CHUM),NA,https://clinicaltrials.gov/ct2/show/NCT04458337,1,0,1,0,3,0,Canada,0,"NA","Journal Article|Multicenter Study|Observational Study|Research Support, Non-U.S. Gov't"
NCT04357938,2020-04-15,2021-04-20,Observational,Risk Stratification With Chest CT to Rule-out Suspected SARS-CoV-2 Infections,"Active, not recruiting",NA,Jena University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04357938,1,0,1,0,1,0,Germany,0,ct-scan,Journal Article|Observational Study
NCT04330261,2020-03-18,2021-03-17,Observational,Clinical Characteristics and Outcomes of Pediatric COVID-19,Recruiting,NA,University of Calgary,NA,https://clinicaltrials.gov/ct2/show/NCT04330261,1,0,1,0,0,0,Canada,0,exposure,"Journal Article|Multicenter Study|Observational Study|Research Support, Non-U.S. Gov't"
NCT04385771,2020-09-01,2021-05-31,Interventional,Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Recruiting,N/A,University Hospital Freiburg,NA,https://clinicaltrials.gov/ct2/show/NCT04385771,1,0,1,0,2,0,Germany,0,vv-ecmo / cytokine adsorption|vv-ecmo|cytokine adsorption,Clinical Trial Protocol|Journal Article
NCT04364893,2020-04-09,2020-10-01,Interventional,Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19,Recruiting,N/A,D'Or Institute for Research and Education,NA,https://clinicaltrials.gov/ct2/show/NCT04364893,1,0,1,0,2,0,Brazil,0,suspension/maintenance of angiotensin receptor blockers/angiotensin-converting enzyme inhibitors|suspension|maintenance|ace inhibitor,Journal Article|Multicenter Study|Pragmatic Clinical Trial|Randomized Controlled Trial
NCT04344145,2020-04-16,2020-05-25,Observational,Exhaustion and Needs in Frontline COVID-19 Healthcare Workers: Cross-sectional Study in a Belgian Population,Completed,NA,UniversitÃ© Libre de Bruxelles,NA,https://clinicaltrials.gov/ct2/show/NCT04344145,1,16,17,0,4,0,Belgium,0,"NA",Journal Article/Journal Article|Practice Guideline
NCT04346602,2020-02-01,2020-06-01,Observational,A Study on the Clinical and Psychological Characteristics of Patients With COVID-2019,Recruiting,NA,Jilin University,NA,https://clinicaltrials.gov/ct2/show/NCT04346602,1,0,1,0,0,0,China,0,all treatment about covid-2019,Journal Article
NCT04345523,2020-04-03,2021-02-28,Interventional,Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients,Recruiting,Phase 2,Puerta de Hierro University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04345523,1,0,1,0,2,0,Spain,0,blood/derivatives|standard care|blood|derivatives.,Clinical Trial Protocol|Journal Article
NCT04403685,2020-05-08,2020-07-08,Interventional,Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,Terminated,Phase 3,BeneficÃªncia Portuguesa de SÃ£o Paulo,Safety,https://clinicaltrials.gov/ct2/show/NCT04403685,1,0,1,0,3,0,Brazil,0,tocilizumab,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04319731,2020-03-20,2021-03-20,Interventional,A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure,Recruiting,Early Phase 1,University of Utah,NA,https://clinicaltrials.gov/ct2/show/NCT04319731,1,0,1,0,1,1,United States,0,human amniotic fluid,Clinical Trial|Journal Article
NCT04471519,2020-07-13,2021-06-30,Interventional,Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers,"Active, not recruiting",Phase 1/Phase 2,Bharat Biotech International Limited,NA,https://clinicaltrials.gov/ct2/show/NCT04471519,1,0,1,1,2,0,India,0,bbv152c - phase i|bbv152b - phase i|bbv152a - phase i|placebo - phase i|bbv152a - phase ii|bbv152b - phase ii,Journal Article
NCT04273321,2020-02-14,2020-04-15,Interventional,Efficacy and Safety of Corticosteroids in COVID-19,Completed,N/A,Beijing Chao Yang Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04273321,1,0,1,0,4,0,China,0,methylprednisolone,Journal Article
NCT04351295,2020-04-20,2020-12-01,Interventional,Efficacy of Faviprevir in COVID-19 Treatment,Recruiting,Phase 2/Phase 3,Tanta University,NA,https://clinicaltrials.gov/ct2/show/NCT04351295,1,0,1,0,2,0,Egypt,0,favipiravir|placebo,Journal Article
NCT04341038,2020-04-01,2020-06-01,Interventional,Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury,Recruiting,Phase 3,Hospital Universitari de Bellvitge,NA,https://clinicaltrials.gov/ct2/show/NCT04341038,1,0,1,0,0,0,Spain,0,tacrolimus|methylprednisolone,Journal Article|Review
NCT04390022,2020-07-31,2020-09-17,Interventional,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Completed,Phase 2,"Clinica Universidad de Navarra, Universidad de Navarra",NA,https://clinicaltrials.gov/ct2/show/NCT04390022,1,0,1,0,6,0,Spain,1,ivermectin|placebo,Journal Article
NCT04451174,2020-06-23,2020-11-30,Interventional,Early Use of Corticosteroids in Non-critical Patients With COVID-19 Pneumonia,Recruiting,Phase 3,University of Chile,NA,https://clinicaltrials.gov/ct2/show/NCT04451174,1,0,1,0,3,0,Chile,0,prednisone,Letter
NCT04394182,2020-04-21,2020-12-31,Interventional,Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,Recruiting,N/A,Fundacion GenesisCare,NA,https://clinicaltrials.gov/ct2/show/NCT04394182,1,10,11,0,0,0,Spain,0,radiotherapy|oxygen|lopinavir/ritonavir|hydroxychloroquine|azithromycin|piperacillin/tazobactam|heparin|corticosteroid|tocilizumab|lopinavir|ritonavir|piperacillin|tazobactam,Journal Article/Journal Article/Journal Article|Review/Editorial|Comment/Journal Article
NCT04354155,2020-06-02,2022-09-30,Interventional,COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial,Recruiting,Phase 2,Johns Hopkins All Children's Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04354155,1,0,1,0,2,1,United States,0,enoxaparin,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04368377,2020-04-06,2020-04-23,Interventional,Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19,Completed,Phase 2,University of Milan,NA,https://clinicaltrials.gov/ct2/show/NCT04368377,1,0,1,0,0,0,Italy,0,tirofiban|clopidogrel|acetylsalicylic acid|fondaparinux,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04394377,2020-06-21,2021-03-31,Interventional,Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial,Recruiting,Phase 4,Brazilian Clinical Research Institute,NA,https://clinicaltrials.gov/ct2/show/NCT04394377,1,0,1,0,6,0,Brazil,0,group 1: rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed|enoxaparin|rivaroxaban|d followed by enoxaparin|heparin|d,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04397510,2020-06-01,2020-12-31,Interventional,Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury,Enrolling by invitation,Phase 4,Frederick Health,NA,https://clinicaltrials.gov/ct2/show/NCT04397510,1,0,1,0,6,1,United States,0,heparin|saline,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04360824,2020-05-06,2021-04-16,Interventional,Covid-19 Associated Coagulopathy,Recruiting,Phase 4,University of Iowa,NA,https://clinicaltrials.gov/ct2/show/NCT04360824,1,0,1,0,4,1,United States,0,thromboprophylaxis|standard of care thromboprophylaxis,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04362085,2020-05-11,2022-03-31,Interventional,Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care,Recruiting,Phase 3,"St. Michael's Hospital, Toronto",NA,https://clinicaltrials.gov/ct2/show/NCT04362085,1,0,1,0,3,0,Canada,0,anticoagulation,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04359212,2020-05-01,2020-06-30,Observational,Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19,Completed,NA,Quovadis Associazione,NA,https://clinicaltrials.gov/ct2/show/NCT04359212,1,0,1,0,3,0,Italy,0,thromboprophylaxis|fondaparinux,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04359277,2020-04-21,2020-09-20,Interventional,A Randomized Trial of Anticoagulation Strategies in COVID-19,Terminated,Phase 3,NYU Langone Health,the PROTECT study is being transitioned to ACTIV4 ACUTE anticoagulation inpatient study,https://clinicaltrials.gov/ct2/show/NCT04359277,1,0,1,0,3,1,United States,0,enoxaparin|anticoagulation,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04401293,2020-04-26,2021-04-26,Interventional,Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients,Recruiting,Phase 3,Northwell Health,NA,https://clinicaltrials.gov/ct2/show/NCT04401293,1,0,1,0,2,1,United States,0,enoxaparin|prophylactic,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04393805,2020-06-01,2020-12-31,Observational,Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto,Recruiting,NA,Quovadis Associazione,NA,https://clinicaltrials.gov/ct2/show/NCT04393805,1,0,1,0,2,0,Italy,0,heparin,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04373707,2020-05-13,2021-11-30,Interventional,Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19,Recruiting,Phase 4,"Central Hospital, Nancy, France",NA,https://clinicaltrials.gov/ct2/show/NCT04373707,1,0,1,0,5,0,France,0,enoxaparin,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04647604,2020-06-23,2021-04-30,Interventional,Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids -,Recruiting,Phase 2,Karolinska University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04647604,1,0,1,0,0,0,Sweden,0,omegavenâ®|sodium chloride,Journal Article|Review
NCT04359836,2020-04-16,2021-04-30,Observational,A Study to Explore the Role of Gut Flora in COVID-19 Infection,Recruiting,NA,ProgenaBiome,NA,https://clinicaltrials.gov/ct2/show/NCT04359836,1,0,1,0,1,1,United States,0,there is no intervention in this study,Journal Article
NCT04411446,2020-08-11,2020-12-15,Interventional,Cholecalciferol to Improve the Outcomes of COVID-19 Patients,Recruiting,Phase 4,Vitamin D Study Group,NA,https://clinicaltrials.gov/ct2/show/NCT04411446,1,1,2,0,3,0,Argentina,0,vitamin d|placebo,Letter
NCT04405908,2020-06-19,2020-10-16,Interventional,SCB-2019 as COVID-19 Vaccine,"Active, not recruiting",Phase 1,Clover Biopharmaceuticals AUS Pty Ltd,NA,https://clinicaltrials.gov/ct2/show/NCT04405908,1,0,1,1,4,0,Australia,0,scb-2019|scb-2019 with as03 adjuvant|scb-2019 with cpg 1018 adjuvant/alum adjuvant|scb-2019 with cpg 1018 adjuvant|alum adjuvant,Journal Article
NCT04371744,2020-04-17,2020-06-04,Observational [Patient Registry],QT-Logs : Artificial Intelligence for QT Interval Analysis of ECG From Smartwatches in Patient Receiving Treatment for Covid-19,Completed,NA,Assistance Publique Hopitaux De Marseille,NA,https://clinicaltrials.gov/ct2/show/NCT04371744,1,0,1,0,1,0,France,0,"NA",Journal Article
NCT04380701,2020-04-23,2023-04-30,Interventional,A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy and Immunocompromised Adults,Recruiting,Phase 1/Phase 2,BioNTech SE,NA,https://clinicaltrials.gov/ct2/show/NCT04380701,1,0,1,1,4,0,Germany,0,bnt162a1|bnt162b1|bnt162b2|bnt162c2,Journal Article
NCT04334954,2020-08-26,2022-03-31,Observational,SARS-COV2 Pandemic Serosurvey and Blood Sampling,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicaltrials.gov/ct2/show/NCT04334954,1,0,1,0,96,1,United States,0,"NA",Preprint
NCT04462393,2020-03-06,2020-05-06,Observational,Characteristics and Outcomes of Patients Admitted to Swedish Intensive Care Units for COVID-19,Completed,NA,Linkoeping University,NA,https://clinicaltrials.gov/ct2/show/NCT04462393,1,0,1,0,1,0,Sweden,0,admission to icu for covid-19,Journal Article
NCT04411784,2020-05-20,2020-07-31,Observational,"PROTECT-ASUC: Covid-19 Pandemic Response Of assessmenT, EndosCopy and Treatment in Acute Severe Ulcerative Colitis","Active, not recruiting",NA,Hull University Teaching Hospitals NHS Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04411784,1,0,1,0,0,0,United Kingdom,0,"NA",Journal Article
NCT04530396,2020-09-07,2021-05-01,Interventional,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19","Active, not recruiting",Phase 3,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,https://clinicaltrials.gov/ct2/show/NCT04530396,1,0,1,1,8,0,Russian Federation,0,gam-covid-vac|placebo,Journal Article
NCT04383574,2020-05-22,2020-08-28,Interventional,Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19),"Active, not recruiting",Phase 1/Phase 2,"Sinovac Biotech Co., Ltd",NA,https://clinicaltrials.gov/ct2/show/NCT04383574,1,0,1,1,2,0,China,0,"two doses of low dosage inactivated sars-cov-2 vaccine at the schedule of day 0,28|two doses of medium dosage inactivated sars-cov-2 vaccine at the schedule of day 0,28|two doses of high dosage inactivated sars-cov-2 vaccine at the schedule of day 0,28|placebo",Journal Article
NCT04466670,2020-07-08,2020-12-30,Interventional,Hemostasis in COVID-19: an Adaptive Clinical Trial,Recruiting,Phase 3,University of Sao Paulo General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04466670,0,36,36,0,0,0,Brazil,0,heparin|acetylsalicylic acid|enoxaparin,"Journal Article|Review/Journal Article/Letter|Comment/Journal Article|Multicenter Study/Journal Article|Review/Comparative Study|Journal Article/Letter/Comparative Study|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article/Clinical Trial, Phase II|Controlled Clinical Trial|Journal Article/Journal Article|Observational Study/Letter"
NCT04333550,2020-04-30,2020-09-30,Interventional,Application of Desferal to Treat COVID-19,Recruiting,Phase 1/Phase 2,Kermanshah University of Medical Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04333550,0,17,17,0,2,0,"Iran, Islamic Republic of",0,deferoxamine,Journal Article
NCT04382768,2020-05-01,2021-01-31,Interventional,Inhaled Ibuprofen to Treat COVID-19,Recruiting,N/A,QuÃ­mica Luar SRL,NA,https://clinicaltrials.gov/ct2/show/NCT04382768,0,3,3,0,3,0,Argentina,0,ibuprofen,Journal Article/Journal Article
NCT04503434,2020-05-15,2020-05-31,Observational [Patient Registry],Patients' Experiences in a Medicalized Hotel for COVID-19 Acute Care Support,Completed,NA,Hospital Clinic of Barcelona,NA,https://clinicaltrials.gov/ct2/show/NCT04503434,0,3,3,0,0,0,Spain,0,"NA",Journal Article
NCT04424953,2020-06-01,2020-12-31,Interventional,To Compare Videolaryngoscope Against Direct Laryngoscope for Intubation When Powered Air Purifying Respirator is Worn,"Active, not recruiting",N/A,Singapore General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04424953,0,17,17,0,2,0,Singapore,0,mcgrath videolaryngoscope|laryngoscope,"Journal Article/Journal Article/Comparative Study|Letter/Journal Article|Research Support, Non-U.S. Gov't"
NCT04445961,2020-05-01,2020-08-14,Observational,Respiratory Mechanics and Gas Exchange in Patients With COVID-19 and Hypoxemic Acute Respiratory Failure,Completed,NA,I.M. Sechenov First Moscow State Medical University,NA,https://clinicaltrials.gov/ct2/show/NCT04445961,0,3,3,0,1,0,Russian Federation,0,respiratory mechanics measurement|gas exchange measurement,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Editorial"
NCT04632615,2020-05-22,2021-02-28,Observational,Sleep Behaviour in Athletes During Home Confinement Due to the Covid-19 Outbreak,Recruiting,NA,Istituto Ortopedico Galeazzi,NA,https://clinicaltrials.gov/ct2/show/NCT04632615,0,8,8,0,0,0,Italy,0,"NA","Journal Article|Observational Study/Journal Article/Journal Article/Journal Article|Research Support, Non-U.S. Gov't"
NCT04369807,2020-04-21,2023-05-31,Observational,Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection,Recruiting,NA,Perspectum,NA,https://clinicaltrials.gov/ct2/show/NCT04369807,0,19,19,0,0,0,United Kingdom,0,mri,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Journal Article/Journal Article/Journal Article|Research Support, Non-U.S. Gov't|Review/Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't|Review/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't"
NCT04542512,2020-10-01,2021-05-31,Observational [Patient Registry],Risk Factors for Necrotic Cholecystitis During COVID-19 Pandemic.,Recruiting,NA,Poissy-Saint Germain Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04542512,0,6,6,0,2,0,France,0,"NA",Journal Article
NCT04482634,2020-09-01,2022-08-31,Interventional,Tele-rehabilitation Versus Home Exercise Program in COVID-19,Recruiting,N/A,KoÃ§ University,NA,https://clinicaltrials.gov/ct2/show/NCT04482634,0,10,10,0,1,0,Turkey,0,remote controlled exercise|home exercise,Journal Article|Review
NCT04359095,2020-08-18,2020-11-30,Interventional,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Recruiting,Phase 2/Phase 3,Universidad Nacional de Colombia,NA,https://clinicaltrials.gov/ct2/show/NCT04359095,0,21,21,0,2,0,Colombia,0,emtricitabine/tenofovir|colchicine pill|rosuvastatin|standard care|emtricitabine|tenofovir,Journal Article
NCT04668404,2020-08-24,2021-01-01,Observational [Patient Registry],Study of Coagulation Profile and Role of Heparin Like Effect in Patients With COVID-19,Recruiting,NA,Postgraduate Institute of Medical Education and Research,NA,https://clinicaltrials.gov/ct2/show/NCT04668404,0,12,12,0,0,0,India,0,sonoclot,Journal Article/Journal Article/Journal Article
NCT04441814,2019-07-23,2021-07-31,Observational,FOUND - Ancillary Study to Smile Protocol NCT03654105,Enrolling by invitation,NA,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",NA,https://clinicaltrials.gov/ct2/show/NCT04441814,0,8,8,0,1,0,Italy,0,"NA","Journal Article|Published Erratum/Journal Article/Journal Article/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Review/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Review"
NCT04511429,2020-06-30,2020-10-31,Observational [Patient Registry],COVID-19 in Immunosuppressed Children,Recruiting,NA,D'Or Institute for Research and Education,NA,https://clinicaltrials.gov/ct2/show/NCT04511429,0,9,9,0,0,0,Brazil,0,"NA",Journal Article/Editorial/Letter
NCT04610554,2020-05-14,2020-10-12,Observational,Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide Early After Mild-to-severe COVID-19,Completed,NA,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",NA,https://clinicaltrials.gov/ct2/show/NCT04610554,0,1,1,0,0,0,Italy,0,"NA",Evaluation Study|Journal Article
NCT04410328,2020-10-21,2021-03-15,Interventional,Aggrenox To Treat Acute Covid-19,Recruiting,Phase 3,"Rutgers, The State University of New Jersey",NA,https://clinicaltrials.gov/ct2/show/NCT04410328,0,5,5,0,4,1,United States,0,dipyridamole er 200mg/ aspirin 25mg orally/enterally/standard of care|standard care|dipyridamole er 200mg|aspirin 25mg orally|enterally,"Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural"
NCT04338568,2020-04-16,2020-11-30,Interventional,Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study,Recruiting,N/A,Hasselt University,NA,https://clinicaltrials.gov/ct2/show/NCT04338568,0,2,2,0,3,0,Belgium,0,lung ultrasound,Journal Article/Evaluation Study|Journal Article
NCT04642326,2020-06-26,2020-07-01,Interventional,Study Investigating the Effects of UVC Beam and Laser Beam Therapy According to Standard Therapy in Patients With Covid-19 Diagnosis,"Active, not recruiting",N/A,RD Global AraÅŸtirma GeliÅŸtirme SaÄŸlik IlaÃ§ InÅŸaat Yatirimlari A.Åž.,NA,https://clinicaltrials.gov/ct2/show/NCT04642326,0,7,7,0,0,0,Turkey,0,test group: experimental - uvc therapy applied,"Clinical Trial|Journal Article|Research Support, Non-U.S. Gov't/Journal Article"
NCT04374786,2020-05-15,2020-09-01,Interventional,Effects of Mobile App in House Staff Health and Well-being During COVID-19 Pandemic,Enrolling by invitation,N/A,University of Arizona,NA,https://clinicaltrials.gov/ct2/show/NCT04374786,0,4,4,0,2,1,United States,0,meditation,Journal Article/Journal Article
NCT04282902,2020-02-04,2020-04-30,Interventional,A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection,Recruiting,Phase 3,Tongji Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04282902,0,4,4,0,0,0,China,0,pirfenidone,Journal Article
NCT04594356,2020-11-19,2021-01-31,Observational,"Assessment of Netosis During COVID-19, Under Treatment With Anakinra, an Interleukin-1 Receptor Antagonist",Recruiting,NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicaltrials.gov/ct2/show/NCT04594356,0,10,10,0,1,0,France,0,"NA",Journal Article|Review
NCT04480034,2020-07-15,2021-01-31,Observational,Obesity Surgery During 2020 Italian Pandemic,Recruiting,NA,University of Roma La Sapienza,NA,https://clinicaltrials.gov/ct2/show/NCT04480034,0,25,25,0,1,0,Italy,0,bariatric procedures,Journal Article/Journal Article|Video-Audio Media/Journal Article/Journal Article|Observational Study
NCT04501965,2020-06-01,2020-08-30,Interventional,Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 Patients,Enrolling by invitation,Phase 2,Institute for Research and Development of Medicinal and Food Plants of Guinea,NA,https://clinicaltrials.gov/ct2/show/NCT04501965,0,19,19,0,1,0,Guinea,0,hydroxychloroquine / azithromycin|quinquina-stevia/azythromycin|4plants/azythromycin|hydroxychloroquine|azithromycin|quinquina-stevia|4plants,Journal Article|Review/Journal Article|Published Erratum
NCT04567927,2020-03-03,2020-05-28,Observational,Prevalence and Risk Factors for Venous Thromboembolic Events in Critically Ill Patients With COVID-19,Completed,NA,"Ente Ospedaliero Cantonale, Bellinzona",NA,https://clinicaltrials.gov/ct2/show/NCT04567927,0,6,6,0,0,0,Switzerland,0,ultrasonography,"Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Observational Study/Journal Article|Research Support, Non-U.S. Gov't/Journal Article"
NCT04459819,2020-03-01,2020-09-30,Observational,Respiratory Physiotherapy in Severe COVID-19 Patients,Recruiting,NA,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",NA,https://clinicaltrials.gov/ct2/show/NCT04459819,0,5,5,0,1,0,Italy,0,respiratory physiotherapy,"Journal Article|Research Support, Non-U.S. Gov't/Journal Article/Journal Article|Practice Guideline"
NCT04631861,2014-01-01,2020-07-31,Observational,Physical Activity and the Risk of COVID-19 Infection and Mortality,Completed,NA,Wonju Severance Christian Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04631861,0,4,4,0,0,0,NA,0,"NA","Journal Article/Journal Article/Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article|Observational Study"
NCT04407468,2020-05-01,2020-07-13,Observational,Awake Prone Positioning and Oxygen Therapy in Patients With COVID-19,Completed,NA,Hospital General San Juan del Rio,NA,https://clinicaltrials.gov/ct2/show/NCT04407468,0,9,9,0,1,0,Mexico,0,prone positioning,Journal Article|Multicenter Study|Observational Study/Comparative Study|Journal Article/Letter/Journal Article/Case Reports|Letter/Journal Article
NCT04374422,2020-04-10,2020-04-12,Observational,COVID-19 Pandemic and Female Sexual Behavior,Completed,NA,Acibadem University,NA,https://clinicaltrials.gov/ct2/show/NCT04374422,0,2,2,0,0,0,Turkey,0,fsfi survey,Journal Article
NCT04442178,2020-09-15,2020-12-30,Interventional,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ),Recruiting,Phase 2,Revimmune,NA,https://clinicaltrials.gov/ct2/show/NCT04442178,0,4,4,0,1,1,United States,0,cyt107|placebo,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04407689,2020-06-08,2021-07-30,Interventional,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort,Recruiting,Phase 2,Revimmune,NA,https://clinicaltrials.gov/ct2/show/NCT04407689,0,2,2,0,2,0,France,0,interleukin|placebo,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04422535,2020-05-29,2020-09-01,Observational,Effects on the Qt Interval of COVID-19 Coronavirus Infection,Recruiting,NA,Hospital General Universitario Gregorio MaraÃ±on,NA,https://clinicaltrials.gov/ct2/show/NCT04422535,0,5,5,0,0,0,Spain,0,"NA","Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't"
NCT04340921,2020-05-14,2021-11-10,Observational,The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury,Recruiting,NA,Barts & The London NHS Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04340921,0,7,7,0,1,0,United Kingdom,0,exposure,"Journal Article|Research Support, Non-U.S. Gov't/Letter"
NCT04497311,2020-06-15,2021-04-30,Observational,Tomographic Findings in COVID-19 and Influenza,Recruiting,NA,Universidad de Guanajuato,NA,https://clinicaltrials.gov/ct2/show/NCT04497311,0,13,13,0,1,0,Mexico,0,thoraxic computed tomography,"Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't|Review/Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't/Journal Article"
NCT04367883,2020-03-01,2022-09-30,Observational,"Influenza Vaccination, ACEI and ARB in the Evolution of SARS-Covid19 Infection",Recruiting,NA,Consorci Sanitari de Terrassa,NA,https://clinicaltrials.gov/ct2/show/NCT04367883,0,1,1,0,3,0,Spain,0,ace inhibitor|arb,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04407169,2020-06-01,2020-11-17,Observational,Prevalence of Critical Forms of CoVid-19 in Patients With Chronic Respiratory Disease,Completed,NA,"Central Hospital, Nancy, France",NA,https://clinicaltrials.gov/ct2/show/NCT04407169,0,4,4,0,1,0,France,0,no intervention,Journal Article
NCT04661631,2020-05-08,2021-07-31,Observational [Patient Registry],Surgery and Lung Ultrasound in COVID-19 Infection,Recruiting,NA,Fundacion Clinica Valle del Lili,NA,https://clinicaltrials.gov/ct2/show/NCT04661631,0,30,30,0,1,0,Colombia,0,lung ultrasound,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Comparative Study|Journal Article/Journal Article|Research Support, Non-U.S. Gov't|Review/Journal Article/Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't/Letter/Journal Article|Research Support, Non-U.S. Gov't/Journal Article/Journal Article|Multicenter Study/Letter|Comment/Journal Article/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review/Journal Article/Journal Article"
NCT04475471,2020-06-11,2021-06-30,Observational,WORLD HEART FEDERATION (WHF) COVID-19 and Cardiovascular Disease Survey,Recruiting,NA,Public Health Foundation of India,NA,https://clinicaltrials.gov/ct2/show/NCT04475471,0,8,8,0,1,0,"Argentina|Bosnia and Herzegovina|Ghana|India|Iran, Islamic Republic of|Sudan",0,"NA","Journal Article|Research Support, Non-U.S. Gov't/Journal Article"
NCT04353674,2020-04-28,2020-12-31,Interventional,Modulation of Hyperinflammation in COVID-19,Recruiting,N/A,Lawson Health Research Institute,NA,https://clinicaltrials.gov/ct2/show/NCT04353674,0,17,17,0,5,0,Canada,0,control|sledd with a l-mod,"Journal Article|Research Support, Non-U.S. Gov't/Letter/Journal Article|Research Support, Non-U.S. Gov't/Journal Article/Journal Article/Journal Article"
NCT04366232,2020-08-19,2020-10-02,Interventional,Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation,Terminated,Phase 2,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,investigator decision,https://clinicaltrials.gov/ct2/show/NCT04366232,0,3,3,0,5,0,France,0,anakinra|anakinra/ruxolitinib|standard care|3)|ruxolitinib,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04368351,2020-03-01,2020-06-30,Observational,Bacteriotherapy in the Treatment of COVID-19,"Active, not recruiting",NA,University of Roma La Sapienza,NA,https://clinicaltrials.gov/ct2/show/NCT04368351,0,4,4,0,1,0,Italy,0,sivomixx|azithromycin|hydroxychloroquine,Journal Article/Journal Article|Systematic Review
NCT04611269,2020-03-20,2020-10-31,Observational [Patient Registry],Clinical Characteristics and Outcomes of Patients With COVID-19 on Mechanical Ventilation in Argentina,Completed,NA,Argentinian Intensive Care Society,NA,https://clinicaltrials.gov/ct2/show/NCT04611269,0,7,7,0,3,0,Argentina,0,"NA","Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't/Journal Article/Editorial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article|Observational Study/Journal Article|Multicenter Study|Observational Study|Research Support, Non-U.S. Gov't"
NCT04577105,2020-04-01,2020-08-31,Observational,Risk Factors and Computed Tomography Findings in COVID-19.,Completed,NA,Instituto Nacional de Cardiologia Ignacio Chavez,NA,https://clinicaltrials.gov/ct2/show/NCT04577105,0,12,12,0,1,0,Mexico,0,simple chest tomography,"Journal Article/Journal Article/Journal Article/Journal Article|Multicenter Study|Observational Study/Journal Article|Research Support, Non-U.S. Gov't|Validation Study"
NCT04627467,2020-03-28,2020-07-09,Interventional,Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID),"Active, not recruiting",Phase 2,Fundacion Clinica Valle del Lili,NA,https://clinicaltrials.gov/ct2/show/NCT04627467,0,20,20,0,0,0,Colombia,0,chloroquine,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Meta-Analysis|Systematic Review/Journal Article/Journal Article/Letter|Comment/Clinical Trial|Journal Article/Historical Article|Journal Article|Review"
NCT04344951,2020-04-06,2021-04-01,Interventional,"Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial",Recruiting,Phase 2,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,NA,https://clinicaltrials.gov/ct2/show/NCT04344951,0,3,3,0,1,0,Greece,0,chloroquine,Journal Article/Journal Article/Clinical Trial|Journal Article
NCT04385043,2020-05-01,2020-10-15,Interventional,Hyperimmune Plasma in Patients With COVID-19 Severe Infection,Recruiting,Phase 2/Phase 3,University of Catanzaro,NA,https://clinicaltrials.gov/ct2/show/NCT04385043,0,3,3,0,0,0,Italy,0,convalescent plasma|standard care,"Clinical Trial, Phase I|Journal Article|Research Support, N.I.H., Extramural"
NCT04517162,2020-08-19,2021-02-19,Interventional,Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients,Recruiting,Phase 1,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicaltrials.gov/ct2/show/NCT04517162,0,31,31,0,2,0,Mexico,0,collagen-polyvinylpyrrolidone,"Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't/Journal Article/Journal Article|Research Support, Non-U.S. Gov't|Validation Study"
NCT04321369,2020-03-09,2020-03-23,Observational,Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals,Completed,NA,UnitedHealth Group,NA,https://clinicaltrials.gov/ct2/show/NCT04321369,0,2,2,0,1,1,United States,0,testing sensitivity for sars-cov-2 virus in symptomatic individuals,Journal Article
NCT04494724,2020-07-13,2020-12-31,Interventional,Clazakizumab vs. Placebo - COVID-19 Infection,Recruiting,Phase 2,The Methodist Hospital System,NA,https://clinicaltrials.gov/ct2/show/NCT04494724,0,8,8,0,0,1,United States,0,clazakizumab|placebo,"Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Published Erratum"
NCT04333875,2020-03-20,2020-12-31,Observational [Patient Registry],Morbidity and Mortality Due to Deferral of Aortic Valve Replacement in Patients With Severe Aortic Stenosis,"Active, not recruiting",NA,"University Hospital Inselspital, Berne",NA,https://clinicaltrials.gov/ct2/show/NCT04333875,0,4,4,0,2,0,Switzerland,0,tavr/savr|tavr|savr,Journal Article/Journal Article
NCT04479202,2020-02-08,2020-04-18,Interventional,The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19,Completed,Phase 4,Chinese Medical Association,NA,https://clinicaltrials.gov/ct2/show/NCT04479202,0,3,3,0,0,0,China,0,berberine|montmorrillonite,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Letter"
NCT04340349,2020-05-11,2021-03-20,Interventional,Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals,Enrolling by invitation,Early Phase 1,Instituto Nacional de Rehabilitacion,NA,https://clinicaltrials.gov/ct2/show/NCT04340349,0,4,4,0,2,0,Mexico,0,hydroxychloroquine|bromhexine hydrochloride|hydroxychloroquine sulfate placebo|bromhexine 8 mg placebo,Journal Article
NCT04384380,2020-04-01,2020-05-31,Interventional,Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19,Completed,N/A,Taoyuan General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04384380,0,5,5,0,1,0,Taiwan,0,hydroxychloroquine,Journal Article|Systematic Review/Clinical Trial|Journal Article
NCT04342637,2020-04-10,2020-04-25,Observational,COVID-19 Endoscopy Survey,Completed,NA,Al-Azhar University,NA,https://clinicaltrials.gov/ct2/show/NCT04342637,0,6,6,0,3,1,"United States|Egypt|Iran, Islamic Republic of",0,practice details,Journal Article|Review/Journal Article/Journal Article|Review
NCT04516811,2020-09-21,2021-12-30,Interventional,Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19,Recruiting,Phase 3,South African National Blood Service,NA,https://clinicaltrials.gov/ct2/show/NCT04516811,0,1,1,0,2,0,South Africa,0,convalescent plasma/standard care|standard care/placebo|convalescent plasma|standard care|placebo,Journal Article
NCT04567979,2020-06-11,2020-09-30,Observational,Prospective Determination of COVID-19 Infection Rate in a Chemotherapy Unit in Mexico.,"Active, not recruiting",NA,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicaltrials.gov/ct2/show/NCT04567979,0,12,12,0,0,0,Mexico,0,"NA","Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Video-Audio Media/Journal Article/Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't/Letter|Comment"
NCT04712292,2020-09-08,2021-01-31,Observational,Effects of COVID-19 Pandemic on the Diagnosis and Outcomes of Colorectal Cancer (COVID-CRC),Recruiting,NA,University of Bologna,NA,https://clinicaltrials.gov/ct2/show/NCT04712292,0,5,5,0,0,0,Italy,0,surgical procedure for cancer,Journal Article|Video-Audio Media/Journal Article/Journal Article/Editorial
NCT04353583,2020-04-21,2021-03-31,Observational [Patient Registry],Renal Outcome in Patients With COVID-19,Recruiting,NA,University of Giessen,NA,https://clinicaltrials.gov/ct2/show/NCT04353583,0,1,1,0,8,0,Germany,0,"NA",Editorial
NCT04392323,2020-05-13,2020-07-01,Interventional,Incidence of COVID-19 Test Conversion in Post-surgical Patients,Recruiting,N/A,Northwell Health,NA,https://clinicaltrials.gov/ct2/show/NCT04392323,0,12,12,0,0,1,United States,0,pcr/serology|pcr|serology test,"Journal Article/Journal Article|Observational Study|Research Support, Non-U.S. Gov't/Journal Article/Case Reports|Journal Article/Journal Article/Journal Article/Journal Article"
NCT04418557,2020-04-28,2021-07-31,Observational [Patient Registry],COVID-19 and Obstetric Transmission,Recruiting,NA,University Hospitals Cleveland Medical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04418557,0,2,2,0,1,1,United States,0,pcr/serology|pcr|serology test,"Case Reports|Journal Article|Research Support, Non-U.S. Gov't"
NCT04515108,2020-03-10,2020-08-05,Observational,Perinatal Outcomes and Hematologic Parameters in COVID-19 Pregnancies,Completed,NA,Ankara City Hospital Bilkent,NA,https://clinicaltrials.gov/ct2/show/NCT04515108,0,4,4,0,0,0,Turkey,0,clinical assessment,Journal Article|Review/Journal Article/Journal Article|Multicenter Study/Journal Article
NCT04393727,2020-05-01,2020-09-30,Interventional,Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19,Terminated,Phase 2,"Azienda Ospedaliero, Universitaria Pisana","Study was stopped because the Promoter was changed and a new study on convalescent plasma
    promoted by AIFA was started in Italy.",https://clinicaltrials.gov/ct2/show/NCT04393727,0,1,1,0,2,0,Italy,0,convalescent plasma,"Case Reports|Journal Article|Research Support, Non-U.S. Gov't"
NCT04356482,2020-05-20,2020-11-30,Interventional,CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19,Recruiting,Phase 1/Phase 2,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,NA,https://clinicaltrials.gov/ct2/show/NCT04356482,0,6,6,0,3,0,Mexico,0,convalescent plasma,"Case Reports|Journal Article|Research Support, Non-U.S. Gov't"
NCT04366089,2020-03-26,2020-10-30,Interventional,Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,Recruiting,Phase 2,Azienda Policlinico Umberto I,NA,https://clinicaltrials.gov/ct2/show/NCT04366089,0,3,3,0,0,0,Italy,0,oxygen-ozone|sivomixx|azithromycin|hydroxychloroquine|standard care,Editorial/Journal Article
NCT04374123,2020-04-20,2020-05-20,Observational,COVID-19 Serology Screening and Strict Protocol in the Endoscopy Unit,Completed,NA,Instituto Ecuatoriano de Enfermedades Digestivas,NA,https://clinicaltrials.gov/ct2/show/NCT04374123,0,3,3,0,1,0,Ecuador,0,igm/igg rapid test|igg antibody test|igm antibodytest,Letter|Comment/Letter|Comment/Journal Article|Multicenter Study
NCT04368897,2020-05-01,2021-04-01,Observational,In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity,Recruiting,NA,"Applied Biology, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04368897,0,4,4,0,3,0,Spain,0,cag,Letter/Journal Article/Letter/Letter
NCT04437940,2020-06-15,2020-07-10,Observational,Evaluation of Vaginal Fluid for Covid-19 Positivity in Women With Positive Nasofarengeal Covid-19 Test,Completed,NA,Acibadem University,NA,https://clinicaltrials.gov/ct2/show/NCT04437940,0,1,1,0,1,0,Turkey,0,pcr,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04378738,2020-05-01,2020-05-07,Interventional,Social Media and Covid19 Pandemic,Enrolling by invitation,N/A,Acibadem University,NA,https://clinicaltrials.gov/ct2/show/NCT04378738,0,1,1,0,0,0,Turkey,0,questionnaire,"Journal Article|Research Support, N.I.H., Extramural"
NCT04424836,2020-05-15,2020-06-04,Observational,HFNC Treatment in COVID-19 Pneumonia,Completed,NA,Sisli Hamidiye Etfal Training and Research Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04424836,0,3,3,0,2,0,Turkey,0,high flow nasal cannula,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04360837,2020-05-06,2021-06-01,Interventional,PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill Corona Virus Disease-19 (COVID-19) Patients,Recruiting,N/A,Szeged University,NA,https://clinicaltrials.gov/ct2/show/NCT04360837,0,1,1,0,2,0,Hungary,0,alveolar,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04346264,2020-04-27,2020-06-01,Observational,CoVid-19 - Infection and Antibody Formation in the Viennese Population,Enrolling by invitation,NA,Ludwig Boltzmann Institute for Lung Health,NA,https://clinicaltrials.gov/ct2/show/NCT04346264,0,1,1,0,1,0,Austria,0,no intervention planned due to the observational study design only a diagnostic testing,"Comparative Study|Letter|Research Support, Non-U.S. Gov't"
NCT04361942,2020-05-01,2020-11-30,Interventional,Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV),Recruiting,Phase 2,Red de Terapia Celular,NA,https://clinicaltrials.gov/ct2/show/NCT04361942,0,4,4,0,2,0,Spain,0,mesenchymal stem cells|placebo,Journal Article
NCT04480593,2020-06-02,2020-08-30,Interventional,The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.,Completed,Phase 2/Phase 3,D'Or Institute for Research and Education,NA,https://clinicaltrials.gov/ct2/show/NCT04480593,0,8,8,0,1,0,Brazil,0,brazilian green propolis extract (epp-af)|standard care,Journal Article|Review/Journal Article|Review/Journal Article|Review
NCT04392713,2020-04-15,2020-07-31,Interventional,Efficacy of Ivermectin in COVID-19,Recruiting,N/A,"Combined Military Hospital, Pakistan",NA,https://clinicaltrials.gov/ct2/show/NCT04392713,0,1,1,0,0,0,Pakistan,0,ivermectin,Journal Article|Review
NCT04453579,2020-03-09,2020-05-04,Observational [Patient Registry],"Bariatric Surgery During Lockdown, Impact of COVID-19 on Physical and Mental Health",Completed,NA,University of Rome Tor Vergata,NA,https://clinicaltrials.gov/ct2/show/NCT04453579,0,1,1,0,0,0,Italy,0,telehealth,Journal Article|Comment
NCT04468035,2020-06-01,2021-12-31,Observational,Early Cognitive Assessment and Evolutionary Monitoring of Patients With Severe ARDS on COVID-19 Pneumonia Requiring Mechanical Ventilation,Recruiting,NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicaltrials.gov/ct2/show/NCT04468035,0,4,4,0,2,0,France,0,"NA",Letter/Case Reports|Journal Article
NCT04530617,2020-10-05,2021-01-31,Interventional,Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients,Recruiting,Phase 2,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicaltrials.gov/ct2/show/NCT04530617,0,28,28,0,3,0,Mexico,0,camostat mesilate|artemisia annua leaf,Published Erratum
NCT04526405,2020-07-14,2020-11-03,Observational,Frequency of COVID-19 Antibodies in Patients With Hereditary Hematological Diseases,Completed,NA,University of Milano Bicocca,NA,https://clinicaltrials.gov/ct2/show/NCT04526405,0,4,4,0,1,0,Italy,0,sars-cov-2 s1/s2 igg|sars-cov-2 s1|igg test,Letter/Letter
NCT04568356,2020-04-24,2020-06-12,Interventional,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,Completed,N/A,"E25Bio, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04568356,0,17,17,0,1,1,United States,0,direct antigen tests for covid-19,"Comparative Study|Journal Article/Journal Article/Evaluation Study|Letter/Journal Article|Research Support, N.I.H., Extramural|Research Support, N.I.H., Intramural|Review/Journal Article/Evaluation Study|Journal Article/Journal Article|Comment/Journal Article|Research Support, Non-U.S. Gov't|Review/Preprint/Evaluation Study|Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Journal Article/Comparative Study|Journal Article|Validation Study/Journal Article/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04673214,2020-12-16,2021-02-02,Interventional,Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment,Recruiting,Phase 3,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,https://clinicaltrials.gov/ct2/show/NCT04673214,0,5,5,0,2,0,Mexico,0,azithromycin / ivermectin / ribaroxaban / paracetamol|azithromycin / ribaroxaban / paracetamol|azithromycin|ivermectin|ribaroxaban|paracetamol,Journal Article|Review
NCT04367896,2020-03-24,2020-04-17,Observational,COVID-19 OUTBREAK AND SOLID ORGAN TRANSPLANTATION (SOT) : AN INTERNATIONAL WEB-BASED SURVEY,Completed,NA,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,NA,https://clinicaltrials.gov/ct2/show/NCT04367896,0,3,3,0,0,0,Italy,0,questionnaire,"Journal Article/Letter|Research Support, Non-U.S. Gov't/Journal Article|Review"
NCT04402853,2020-02-01,2020-03-01,Observational,SARS Cov-2 in Conjunctival Secretion in COVID-19 Patients,Completed,NA,UniversitÃ  degli Studi dell'Insubria,NA,https://clinicaltrials.gov/ct2/show/NCT04402853,0,1,1,0,1,0,Italy,0,tears swab,Journal Article
NCT04616950,2020-12-01,2021-06-30,Observational,Impact of the COVID-19 Epidemic on the Hospital Journey of Patients With Cancer of the Digestive System,Recruiting,NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicaltrials.gov/ct2/show/NCT04616950,0,5,5,0,2,0,France,0,"NA",Journal Article|Review/Journal Article
NCT04488484,2020-07-01,2021-12-31,Interventional,Medical and Serological Follow-up of the Staff of the Paris Saint-Joseph Hospital Group Infected With Severe Acute Respiratory Syndrome Coronavirus 2.,"Active, not recruiting",N/A,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicaltrials.gov/ct2/show/NCT04488484,0,5,5,0,1,0,France,0,serology test follow-up,"Journal Article|Systematic Review/Journal Article|Research Support, Non-U.S. Gov't"
NCT04522492,2020-08-11,2021-03-31,Interventional,Impact of COVID-19 on Mental Health of Patients With Skin Picking,"Active, not recruiting",N/A,Hospital de Clinicas de Porto Alegre,NA,https://clinicaltrials.gov/ct2/show/NCT04522492,0,2,2,0,1,0,Brazil,0,internet-based cognitive behavioral therapy|quality of life promotion,Journal Article|Randomized Controlled Trial
NCT04689672,2020-12-16,2021-05-10,Observational,Predictivity of Hemogasanalysis and Lung UltraSound in Determining COVID-19 Severity,Recruiting,NA,IRCCS San Raffaele,NA,https://clinicaltrials.gov/ct2/show/NCT04689672,0,5,5,0,0,0,Italy,0,lung ultrasound,Letter
NCT04647695,2020-11-20,2021-07-31,Interventional,IFN-beta 1b and Remdesivir for COVID19,Recruiting,Phase 2,The University of Hong Kong,NA,https://clinicaltrials.gov/ct2/show/NCT04647695,0,2,2,0,2,0,Hong Kong,0,interferon|remdesivir,"Clinical Trial, Phase III|Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04454606,2020-05-01,2020-05-15,Interventional,The New Silicone N99 Half-Piece Respirator,Completed,N/A,Bangkok Metropolitan Administration Medical College and Vajira Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04454606,0,1,1,0,0,0,Thailand,0,fit test|filtration test,Journal Article|Published Erratum
NCT04733729,2020-03-01,2021-01-30,Observational [Patient Registry],Covid-19 in Hematological Malignancies,Recruiting,NA,Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne,NA,https://clinicaltrials.gov/ct2/show/NCT04733729,0,3,3,0,1,0,Italy,0,"NA","Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article|Multicenter Study|Observational Study/Journal Article|Multicenter Study|Observational Study|Research Support, Non-U.S. Gov't"
NCT04443140,2020-03-15,2020-07-01,Observational [Patient Registry],Preeclampsia-like Syndrome Induced by COVID-19: Is it a Real Public Health Issue in Pregnancy During the Pandemic?,Completed,NA,Zeynep Kamil Maternity and Pediatric Research and Training Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04443140,0,1,1,0,2,0,Turkey,0,pcr,Journal Article|Observational Study
NCT04558996,2020-03-01,2020-12-31,Observational [Patient Registry],Spanish Registry of Pregnant Women With COVID-19,Recruiting,NA,Puerta de Hierro University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04558996,0,1,1,0,0,0,Spain,0,"NA",Letter
NCT04449731,2020-03-20,2020-08-30,Observational,Changes in Dietary Behaviours During the COVID-19 Outbreak Confinement in the Adult Population (COVIDiet_Int),Recruiting,NA,Universidad de Granada,NA,https://clinicaltrials.gov/ct2/show/NCT04449731,0,2,2,0,3,0,Spain,0,"NA",Journal Article/Journal Article
NCT04643522,2020-01-07,2020-10-05,Observational,Semen Parameters and COVID-19 in Infertile Men,Completed,NA,Ankara City Hospital Bilkent,NA,https://clinicaltrials.gov/ct2/show/NCT04643522,0,4,4,0,1,0,Turkey,0,clinical assessment,Journal Article/Journal Article/Journal Article/Journal Article
NCT04517422,2020-08-19,2021-01-31,Interventional,Efficacy of L. Plantarum and P. Acidilactici in Adults With SARS-CoV-2 and COVID-19,"Active, not recruiting",N/A,"AB Biotics, SA",NA,https://clinicaltrials.gov/ct2/show/NCT04517422,0,7,7,0,5,0,Mexico,0,probiotics|placebo,Journal Article/Journal Article/Journal Article|Review/Journal Article/Journal Article/Journal Article
NCT04343898,2020-04-01,2020-08-01,Observational,Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19,"Active, not recruiting",NA,Brigham and Women's Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04343898,0,8,8,0,8,1,United States,0,no intervention,"Clinical Trial|Letter|Multicenter Study|Research Support, N.I.H., Extramural/Journal Article/Journal Article|Multicenter Study/Journal Article|Research Support, N.I.H., Extramural/Journal Article|Multicenter Study|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Letter|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article/Journal Article|Research Support, N.I.H., Extramural"
NCT04476589,2020-07-01,2022-06-30,Observational,Prognostication of Recovery in Early Disorders of Consciousness After COVID-19,Recruiting,NA,Massachusetts General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04476589,0,1,1,0,1,1,United States,0,functional mri,"Case Reports|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04679168,2020-06-01,2021-12-31,Observational [Patient Registry],Study on Kidney Disease and EnviromenTal Chemical,Recruiting,NA,Seoul National University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04679168,0,3,3,0,1,0,"Korea, Republic of",0,"NA",Journal Article
NCT04685512,2020-11-18,2021-04-01,Interventional,Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged Home,Recruiting,Phase 2/Phase 3,"University Hospital, Caen",NA,https://clinicaltrials.gov/ct2/show/NCT04685512,0,5,5,0,0,0,France,0,tenofovir disoproxil/emtricitabine|tenofovir disoproxil|emtricitabine,"Journal Article|Research Support, N.I.H., Extramural"
NCT04514705,2020-08-11,2021-12-31,Interventional,Characteristics in Post Covid-19 Patients,Recruiting,N/A,Universidade Metodista de Piracicaba,NA,https://clinicaltrials.gov/ct2/show/NCT04514705,0,6,6,0,0,0,Brazil,0,exercise,"Editorial/Case Reports|Journal Article/Journal Article|Research Support, Non-U.S. Gov't|Systematic Review/Journal Article/Journal Article"
NCT04662437,2020-09-10,2020-12-01,Observational,The Status of Parathyroid Hormone Secretion in Covid-19 Patients,Completed,NA,Bezmialem Vakif University,NA,https://clinicaltrials.gov/ct2/show/NCT04662437,0,3,3,0,0,0,Turkey,0,venous blood was collected for biochemistry testing,Journal Article|Review/Letter
NCT04578158,2020-09-29,2021-04-28,Interventional,Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19,Recruiting,Phase 2/Phase 3,Liaquat University of Medical & Health Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04578158,0,3,3,0,7,0,Pakistan,0,standard covid-19 care|quercetin phytosome,Journal Article/Journal Article
NCT04604249,2020-10-26,2021-11-30,Observational,Prevalence of COVID-19 in High Altitude : Insights From the Highest City of the World,"Active, not recruiting",NA,Centre d'Expertise sur l'Altitude EXALT,NA,https://clinicaltrials.gov/ct2/show/NCT04604249,0,6,6,0,1,0,Peru,0,"sars-cov-2 rapid diagnostic test (covid-prestoâ® igm/igg, aaz, boulogne-billancourt, france)|sars-cov-2 rapid diagnostic test (covid-prestoâ® igm|igg, aaz, boulogne-billancourt, france)",Letter|Comment/Journal Article/Journal Article/Letter|Comment
NCT04700254,2020-12-28,2021-01-11,Observational,"Anxiety, Depression and Eating Attitudes of Diabetes Mellitus Patients During COVID-19 Lockdown in Greece",Completed,NA,"Chania General Hospital ""St. George""",NA,https://clinicaltrials.gov/ct2/show/NCT04700254,0,5,5,0,4,0,Greece,0,dass questionnaire|eat-26 questionnaire,Journal Article
NCT04486508,2020-07-30,2020-11-19,Interventional,Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19,Recruiting,Phase 3,Rajaie Cardiovascular Medical and Research Center,NA,https://clinicaltrials.gov/ct2/show/NCT04486508,0,1,1,0,5,0,"Iran, Islamic Republic of",0,intermediate dose enoxaparin/ unfractionated heparin|standard prophylactic dose enoxaparin/ unfractionated heparin|atorvastatin|placebo|enoxaparin|heparin|standard prophylactic dose enoxaparin,Clinical Trial Protocol|Journal Article
NCT04659200,2020-09-01,2020-12-05,Observational,Thyroid Function Tests and Status of Thyroid Autoantibodies in Covid-19 Patients,Completed,NA,Bezmialem Vakif University,NA,https://clinicaltrials.gov/ct2/show/NCT04659200,0,1,1,0,2,0,Turkey,0,venous blood was collected for biochemistry testing.,Journal Article
NCT04705753,2020-04-01,2020-10-15,Interventional,"Assessment of the Clinical Effectiveness of a Herbal Extract (Cretan IAMA) in Patients With Viral Respiratory Infections, Including COVID-19, in Primary Healthcare Settings, and Co-assessment of Its Prophylactic Effect in People Cohabiting With These Patients",Completed,Phase 2/Phase 3,University of Crete,NA,https://clinicaltrials.gov/ct2/show/NCT04705753,0,4,4,0,0,0,Greece,0,cretan iama,Journal Article|Review
